

---

This is the **accepted version** of the journal article:

Voltà-Durán, Eric; Parladé Molist, Eloi; Serna, Naroa; [et al.]. «Endosomal escape for cell-targeted proteins. Going out after going in». *Biotechnology advances*, Vol. 63 (March-April 2023), art. 108103. DOI 10.1016/j.biotechadv.2023.108103

---

This version is available at <https://ddd.uab.cat/record/283745>

under the terms of the  license

# 1 Endosomal escape for cell-targeted proteins. Going out 2 after going in

3 Eric Voltà-Durán <sup>1,2,3</sup>, Eloi Parladé <sup>1,2,3</sup>, Naroa Serna <sup>1,2,3,&</sup>, Antonio Villaverde  
4 <sup>1,2,3, \*</sup>, Esther Vazquez <sup>1,2,3, \*</sup> and Ugutz Unzueta <sup>2,3,4,5,\*</sup>

5  
6 <sup>1</sup> Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193  
7 Cerdanyola del Vallès (Barcelona), Spain.

8 <sup>2</sup> CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos  
9 III, 08193 Cerdanyola del Vallès (Barcelona), Spain.

10 <sup>3</sup> Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193  
11 Cerdanyola del Vallès (Barcelona), Spain.

12 <sup>4</sup> Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain.

13 <sup>5</sup> Josep Carreras Leukaemia Research Institute, 08916 Badalona (Barcelona), Spain.

14 & Present address: Nanoligent SL. Edifici Eureka, Universitat Autònoma de Barcelona, Bellaterra,  
15 08193 Barcelona, Spain.

16 \* Corresponding Authors:

17 AV antonio.villaverde@uab.cat

18 EV esther.vazquez@uab.cat

19 UU uunzueta@santpau.cat

20

21

22

23

24

25

26

27

28

29

30

31 **Abstract:**

32 Protein-based nanocarriers are versatile and biocompatible drug delivery systems. They  
33 are of particular interest in nanomedicine as they can recruit multiple functions in a  
34 single modular polypeptide. Many cell-targeting peptides or protein domains can  
35 promote cell uptake when included in these nanoparticles through receptor-mediated  
36 endocytosis. In that way, targeting drugs to specific cell receptors allows a selective  
37 intracellular delivery process, avoiding potential side effects of the payload. However,  
38 once internalized, the endo-lysosomal route taken by the engulfed material usually  
39 results in full degradation, preventing their adequate subcellular localization,  
40 bioavailability and subsequent therapeutic effect. Thus, entrapment into endo-  
41 lysosomes is a main bottleneck in the efficacy of protein-drug nanomedicines.  
42 Promoting endosomal escape and preventing lysosomal degradation would make this  
43 therapeutic approach clinically plausible. In this review, we discuss the mechanisms  
44 intended to evade lysosomal degradation of proteins, with the most relevant examples  
45 and associated strategies, and the methods available to measure that effect. In addition,  
46 based on the increasing catalogue of peptide domains tailored to face this challenge as  
47 components of protein nanocarriers, we emphasize how their particular mechanisms of  
48 action can potentially alter the functionality of accompanying protein materials,  
49 especially in terms of targeting and specificity in the delivery process.

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65 **Keywords:**

66 Protein nanocarriers, Protein engineering, Targeting, Endosomal Escape.

67

## 68 **1. Introduction:**

69 Drug targeting is an urgent and unmet need in molecular medicine and especially in  
70 oncology, where most of the administered drugs display potent cytotoxic effects (Bazak  
71 et al., 2015). In this sense, cell-specific drug delivery is usually explored through the  
72 development of nanoscale drug carriers (Raj et al., 2021), that are functionalized with  
73 ligands for specific cell surface molecules overexpressed in target cells (Jiang et al.,  
74 2019). For that, a nanoscale size reached through the self-assembly of building blocks  
75 into homo-oligomers is particularly convenient to favor the intended biodistribution, to  
76 exploit the enhanced retention and permeability effect (EPR), and to allow multiple  
77 display of the cell ligand for cooperative receptor binding, resulting into highly selective  
78 cell penetrability through endosomal routes (Duncan and Gaspar, 2011).

79 In this context, cell-targeted delivery systems, in form of functional nanoparticles, are  
80 being developed as promising nanomedical tools. Among the diversity of materials  
81 explored to construct suitable nanoparticles, proteins represent an emerging and very  
82 useful category of biomaterials. This is because of their full biocompatibility,  
83 biodegradability and easy production in cell factories (Corchero et al., 2014), together  
84 with their capability to tailor many of the functions valuable in nanomedicine such as  
85 self-assembly or specific molecular recognition and binding. In addition, the  
86 extraordinary plasticity of protein materials allows the recruitment of different  
87 functional domains such as targeting ligands, architectonic tags or nuclear localization  
88 signals, in a single multifunctional polypeptide by simple genetic fusion (Ferrer-Miralles  
89 et al., 2015; Vazquez et al., 2009). In this regard, protein drugs can be also incorporated  
90 to such constructs resulting in unique species of protein-only, self-organized nanosized  
91 therapeutics (Casanova et al., 2019; Serna et al., 2018).

92 Cell-targeted protein delivery usually relies on receptor-mediated endocytic processes,  
93 in which early endosome vesicles rapidly mature into late endosomes and finally fuse  
94 with lysosomes. This fusion leads to the complete degradation of the engulfed protein  
95 material by lysosomal enzymes and acidic conditions (Bareford and Swaan, 2007;  
96 Huotari and Helenius, 2011). Since most of delivered drugs, including proteins, do not  
97 perform their activities in lysosomes but in the cell cytoplasm or in other subcellular  
98 compartments, internalized nanomaterials usually need to be efficiently released from  
99 endosomes to reach their intracellular therapeutic target (Lee et al., 2019). Thus, the  
100 entrapment of protein-based therapeutics into endo-lysosomes is a main reason for  
101 their limited efficacy (Erickson et al., 2006; LeCher et al., 2017; Pirie et al., 2011). Some  
102 strategies as the incorporation of non-natural amino acids are intended to delay protein  
103 degradation within the lysosomes (Kato et al., 2016; Yamashita et al., 2014). However,  
104 these strategies could complement but not replace the incorporation of efficient  
105 endosomal escape (EE) agents, including peptides or protein domains, which are  
106 mandatory to protect their final functionality. To such end, peptides with endosome-  
107 disrupting capacities have been recruited into protein constructs through genetic fusion  
108 to act in cis, fitting the modular setting (Ahmad et al., 2019; Varkouhi et al., 2011).  
109 However, most of the described EE peptides act through fusogenic or pore-forming  
110 activities, that being receptor-independent usually promote unspecific cell interactions  
111 and penetration, which can potentially impair the highly desired specific cell binding  
112 capacities of targeted constructs (Sánchez-García et al., 2017; Serna et al., 2019;  
113 Varkouhi et al., 2011). Therefore, although current nanomedical approaches have

114 already developed a huge armamentarium of EE peptides, it is critical to evaluate which  
115 of them are potentially suitable to be incorporated into targeted delivery platforms,  
116 without affecting their cell specificity throughout the delivery process.

117 Taking all these points into consideration, the rational design of protein nanocarriers  
118 devoted to targeted intracellular delivery of protein-based and chemical drugs or  
119 imaging agents, that are sensitive to lysosomal degradation, should look forward to the  
120 incorporation of efficient EE peptides that do not interfere into receptor-mediated  
121 internalization. In addition, the fine evaluation of EE also requires very accurate  
122 analytical tools especially refined for such purpose. Altogether, this review aims to  
123 discuss the different mechanisms of action employed by currently described EE  
124 peptides, focusing on their potential interference over cell-surface receptor targeting.  
125 Moreover, we will also discuss the recent advances in the methods used to track these  
126 processes, highlighting the EE protein domains that have already been empirically tested  
127 for receptor-targeted delivery approaches as well as the ones predicted to be especially  
128 suited for that.

## 129 **2. Mechanisms of endosomal escape**

130 Understanding the particular mechanisms used by different peptides and protein  
131 domains to control the EE of proteins is a key element for the proper rational design of  
132 protein-based nanomedicines (Mejia et al., 2022; Pei, 2022). For that, it is important to  
133 note that in the context of cell-targeted proteins, EE peptides are usually recruited  
134 within the same modular polypeptide (in cis) in order to induce the EE of the whole  
135 protein after receptor-mediated endocytosis. In this sense, although some particular  
136 peptides are supposed to induce the EE of accompanying proteins in trans, they could  
137 also potentially induce the release of their neighbor internalized polypeptides when  
138 incorporated in cis in a fusion protein. In some cases, the incorporation of a furin  
139 cleavable site between the different protein modules is also mandatory to allow the  
140 endosomal cleavage of the EE domain from the polypeptide to further induce the EE of  
141 the cargo protein in trans. All together, the most studied approaches involve the use of  
142 membrane fusion peptides (Ahmad et al., 2019) or pore-forming peptides (LeCher et al.,  
143 2017) among other more sophisticated strategies.

### 144 **2.1 Pore formation.**

145 Highly cationic peptides are widely known to induce pore formation in lipid bilayers.  
146 They act through three main mechanisms accounted by the barrel stave, carpet or  
147 toroidal models (Figure 1A) (Matsuzaki, 2019; Priyadarshini et al., 2022). The barrel-  
148 stave model involves the self-assembly of a pore-forming peptide on the surface of the  
149 membrane for the subsequent internalization of the protein or oligomer through the  
150 hydrophobic region of the lipid bilayer, creating a channel (Figure 1A, i). The carpet  
151 model, however, implies a dual-step mechanism in which the oligomerization of the  
152 protein is not necessary to create the pore. Instead, the pore-forming peptide binds to  
153 lipids on the membrane through electrostatic interactions, covering the surface.  
154 Eventually, upon reaching an adequate concentration, a consequent micellization occurs  
155 and leads to the membrane dissolution (Figure 1A, ii). Finally, the toroidal mechanism  
156 also involves a dual step process in which the pore-forming peptide is first oriented in  
157 parallel to the lipid bilayer to be then reoriented perpendicularly to penetrate the  
158 hydrophobic region of the membrane. Thus, along with some lipid molecules, they form

159 lipid-lined pores and contiguous membrane leaflets that result in an irreversible rupture  
160 of the membrane (Figure 1A, iii).

### 161 2.1.1 Pore-forming peptides in endosomal escape.

162 Some authors have claimed the use of pore-forming peptides as EE promoters.  
163 However, it is important to note that being highly cationic, most of them can also  
164 interact with extracellular membranes. Arginine-rich cell penetrating peptides (CPP)  
165 such as TAT, Penetratin or 8R are clear examples of this kind of pore-forming motifs,  
166 which show interesting endosomolytic activities and can also induce unspecific cell  
167 uptake via micropinocytosis (Lönn and Dowdy, 2015). In this regard, the dimeric  
168 fluorescent TAT (dfTAT) has been engineered as a potent and non-toxic endosomolytic  
169 agent that efficiently induces the cytosolic leakage of accompanying molecules in late  
170 endosomes (Erazo-Oliveras et al., 2016, 2014). However, dfTAT was proven to also  
171 penetrate cells majorly through micropinocytosis (Allen et al., 2018), which makes it a  
172 poor candidate as a partner domain in targeted delivery settings.

173 Some other pore-forming peptides have exhibited intrinsic cytotoxic effects, which  
174 makes them also unsuited for general drug delivery purposes. This set includes the  
175 antimicrobial peptide (AMP) GWH1 and other bacterial peptides such as the  
176 pneumococcal pneumolysin (Browne et al., 1999), streptococcal streptolysin O (SLO)  
177 (Browne et al., 1999) or the *Listeria* listeriolysin O (LLO) (Plaza-GA et al., 2019). Similar  
178 problems were reported for the bee venom-derived peptide melittin, whose cell  
179 membrane-disrupting activities produced high cell toxicity at neutral pH (Kandil et al.,  
180 2019; Paray et al., 2021). However, the engineering of novel peptide analogs with  
181 reduced cell cytotoxicity and enhanced endosome-selective pore-forming activity has  
182 recently generated growing interest (Paray et al., 2021). In this regard, the substitution  
183 of basic residues for glutamic acids in melittin and two other membrane-disrupting  
184 AMPs (LL-37 and bombolitin V) produced pH-sensitive analogs with selective membrane  
185 disrupting activity at low pH (pH 5.0), with no evidence of cell membrane permeability  
186 or toxicity at neutral pHs (Ahmad et al., 2015). The same occurs with the novel synthetic  
187 leucine zipper endosomolytic peptide (LZEP), whose pore-forming ability is obtained  
188 only under acidic conditions (Ahmad et al., 2021). In a similar way, Aurein 1.2 is an AMP  
189 of animal origin that selectively disrupts endosomal membranes via the carpet  
190 mechanism (Fernandez et al., 2012). Thus, it enhances the EE of cargo proteins *in vitro*  
191 and *in vivo* with no toxicity over mammalian cells (Li et al., 2015). Recently, Aurein 1.2  
192 has been successfully conjugated to an EGFR-targeted fluorescent protein, promoting  
193 improved intracellular protein accumulation without affecting its specificity or  
194 functionality (Lieser et al., 2022).

195 Related to that, in an attempt to selectively target other pore-forming peptides to  
196 cancer cells, the AMP Ceratotoxin A (CtxA) was also recently conjugated to folic acid and  
197 tested over folate-receptor overexpressing KB cancer cells (Mayer et al., 2019). In this  
198 sense, CtxA is a 36-aa cationic peptide that efficiently forms pores into cell membranes  
199 following the barrel stave model. However, and opposed to expected, folic-acid targeted  
200 CtxA (CtxA-FA) showed no difference over KB cancer cells compared to wild type CtxA  
201 (Mayer et al., 2019). Similar results were also reported for a Her2-targeted listeriolysin  
202 O (LLO) (Fotoohi-Ardakani et al., 2019). In contrast, recent work targeting LLO to LHRH-  
203 receptor showed some extend of target-cell selectivity (Kheirandish et al., 2019).

204 Nevertheless, all these AMPs exerted their pore-forming activity over external cell  
205 membranes, showing no specificity for endosomes.

206 In summary, despite being quite useful to promote the cytosolic delivery of some  
207 accompanying proteins, cationic pore-forming peptides still display important cell  
208 penetrating properties that are generally accompanied with unspecific targeting and cell  
209 membrane-lysis associated toxicities. Therefore, unless adapted to exhibit endosome-  
210 selective activities, they may not be the most appropriate choice when dealing with  
211 targeted delivery approaches. Related to that, the described attempts to selectively  
212 target pore-forming peptides to cancer cells were in general not very encouraging either  
213 (Fotoohi-Ardakani et al., 2019; Kheirandish et al., 2019; Mayer et al., 2019).

## 214 **2.2. Fusion with lipid membranes.**

215 Some peptides are able to induce the release of the endosomal content by driving the  
216 fusion of lipid membranes they are embedded in with the endosomes. This class of  
217 peptides are usually rich in bulky hydrophobic residues and show large proportions of  
218 glycine and alanine residues (Pei and Buyanova, 2019). Thus, a change in the pH during  
219 the endosome maturation process induces a conformational shift in the peptide, which  
220 exposes the hydrophobic residues that interact then with the endosomal membranes.  
221 This particular mechanism of action is extensively present in viral proteins (Pal, 2021;  
222 Somiya and Kuroda, 2020). As a representative example (Figure 1B), the well-known  
223 fusogenic protein from the influenza virus hemagglutinin-2 (HA2) undergoes a  
224 conformational change at acidic pH due to the protonation of glutamate and aspartate  
225 residues. Consequently, the hydrophobic residues of the peptide become exposed and  
226 trigger the fusion of the free HA2 end to the endosomal membrane. Thus, both ends of  
227 the same HA2 polypeptide become embedded in two parallel (viral and endosomal)  
228 membranes. Finally, the protein folds into a hairpin-like conformation that approaches  
229 both protein ends leading to a close contact of the two membranes which eventually  
230 fuse (Worch, 2014).

### 231 *2.2.1 Fusogenic peptides in endosomal escape*

232 Most of the EE peptides described in the literature act as fusogenic peptides. This  
233 category includes peptides with viral (HA2, L2, gp41, gpH, WNV-ENV, INF-7 or DEN),  
234 animal (B18), synthetic (KALA, GALA or GALA3) or even human (S19) origin (Varkouhi et  
235 al., 2011). As stated, the HA2 peptide and its derivatives (as INF-7) are the most  
236 representative members of this group (Lin et al., 2014; Sung et al., 2013). However,  
237 although having shown potential in targeted delivery approaches (Liu et al., 2017; Sala  
238 et al., 2019) there are still important concerns about whether the peptides remain  
239 attached to endosomal membranes after promoting their lysis (Lee et al., 2011) and the  
240 influence of these agents over the selectivity of proteins intended to be delivered in a  
241 targeted way (Lee et al., 2011; Lieser et al., 2022; Sánchez-García et al., 2017).

242 Similar worries arise with the use of GALA, a synthetic amphipathic peptide consisting  
243 in EALA (glutamic acid, alanine, leucine, alanine) repetitions, whose activity is based on  
244 glutamic acid protonation at acidic pH (Nakase et al., 2011). Thus, the incorporation of  
245 specific acidic amino acids (Glu) in the sequence has served to generate a pH-sensitive  
246 peptide, whose charge completely changes from physiological to acidic pH, resulting in  
247 a pH-selective membrane interaction activity (Ahmad et al., 2019). In this sense, despite

248 maintaining some specificity in a targeted approach(Lieser et al., 2022), GALA has failed  
249 to induce the cytosolic release of some proteins due to its high hydrophobicity and  
250 tendency to aggregate on the plasma membrane (Li et al., 2020). A rationally-modified  
251 version (GALA3) with reduced repeated units of EALA has successfully solved this  
252 problem and has efficiently induced the EE of a non-targeted fusion protein (Li et al.,  
253 2020). However, further exploration is required to determine the suitability of this new  
254 version for targeted delivery settings.

255 Related to that, the PreS2-domain of the hepatitis-B virus surface antigen is one of the  
256 first reported fusogenic peptides that despite being described as a cell permeable motif  
257 (Oess and Hildt, 2000) has been used to promote the cytosolic delivery of an EGFR-  
258 targeted protein (Saporin), reducing its side effects and enhancing its antitumor activity  
259 in vivo (Fuchs et al., 2007). The 19-aa peptide DEN (from the Dengue virus envelope  
260 protein) is another recently reported fusogenic peptide (Huang et al., 2010) that, by  
261 showing selective affinity for specific lipids present in the late endosomes (Zaitseva et  
262 al., 2010), has also been successfully used in targeted delivery approaches (Kiesgen et  
263 al., 2014). In this sense, the addition of DEN efficiently promoted the *in vitro* cytotoxic  
264 activity of an EGFR-targeted Ranpirinase (RNase) without affecting its cells selectivity  
265 (Kiesgen et al., 2014). Therefore, enlightened by the promising applicability of these  
266 peptides in targeted delivery, their potential immune reactivity, derived from their viral  
267 origin, needs to be still addressed.

268 A similar concern was raised regarding the use of the 18-aa fusogenic peptide (B18) from  
269 the sea urchin fertilization protein (animal origin) that was successfully used for the  
270 intracellular delivery a of TAT-guided GFP protein (Niikura et al., 2015) and in an EGFR-  
271 targeted approach (Niikura et al., 2016). To solve this problem, a potentially less  
272 immunogenic 19-aa fusogenic peptide (S19) derived from the human protein syncytin 1  
273 has been recently described by the same group and successfully used to enhance the  
274 intracellular delivery of different proteins including GFP, SNAP-tag or  $\beta$ -galactosidase  
275 into mammalian cells in absence of cytotoxicity (Sudo et al., 2017). However, although the  
276 reported assays suggested an endosome-specific affinity of S19, cell uptake was still  
277 induced by TAT-mediated micropinocytosis in the tested proteins. Therefore, its real  
278 influence over a targeted setting is yet to be determined.

279 All in all, the use of fusogenic peptides that undergo conformational changes at acidic  
280 pH and that therefore become active at late endosomes, is an attractive strategy  
281 because of their small size, presumable endosome-specificity and lack of cell toxicity.  
282 Nevertheless, it is still unclear how peptides that promote fusion between lipidic  
283 membranes (which makes them extremely appealing for membrane-based delivery  
284 approaches such as liposomes) can assist the release of proteins without a lipidic  
285 envelope from the endosomal lumen to the cytosol. Therefore, although some  
286 promising peptides as B18, DEN or S19 have already been reported, further exploration  
287 is needed to better understand their particular mechanism of action and determine if  
288 their general use in targeted delivery settings is a near reality or not.

### 289 **2.3 Proton-sponge mechanism**

290 Basic amino acids are hydrophilic, polar and cationic in nature. In this sense, histidine is  
291 the only basic amino acid that is found deprotonated at physiological pH and becomes  
292 protonated at slightly lower pH (pKa = 6) (He et al., 2020). During the acidification



293 process of endosomes, the imidazole ring of histidine gets protonated, accepting  
294 hydrogen molecules from the medium and neutralizing the endosomal pH. This fact  
295 results in an increased active transport of hydrogen protons inside the endosomes along  
296 with an influx of chloride ions to reach the desired pH. In consequence, a passive  
297 transport of water molecules into the endosomes promotes their osmotic swelling and  
298 subsequent lysis. This event is known as the proton sponge effect (Figure 1C). Based on  
299 such principle, the presence of histidine residues in a given protein sequences has  
300 already been reported to assist its endo-lysosomal escape (Liu et al., 2022; Váňová et  
301 al., 2022).

### 302 *2.3.1 Histidine-rich peptides in endosomal escape*

303 Genetic fusion of histidine tags, mainly hexahistidine, is a very common procedure in  
304 biotechnology, not only to allow immobilized metal affinity chromatography (IMAC) of  
305 recombinant proteins but also, as an architectonic tag for protein assembly as nanoscale  
306 entities (López-Laguna et al., 2022). In this context, the role of polyhistidines as EE  
307 peptides has gained increasing interest and has been extensively studied, especially in  
308 targeted drug delivery, as such peptides do not interfere with the targeting properties  
309 of the protein (Dhankher et al., 2021; Yu et al., 2021). Interestingly, and as an additional  
310 feature, the incorporation of hexahistidine tags in a carrier protein allows its direct  
311 release into the cytosol through the proton sponge effect, avoiding any need to interact  
312 with lipid bilayers. Being then hexahistidine peptides appealing in drug delivery, their  
313 potential immunogenicity has been recently addressed by the generation of humanized  
314 histidine-rich variants that retain endosomolytic properties while still allowing an  
315 efficient purification via IMAC (López-Laguna et al., 2020).

316 Other histidine-rich peptides have also been used to induce the cytosolic release of  
317 proteins intended for targeted delivery. As an example, the peptide ppTG21 successfully  
318 promotes the endosomal escape of CRISPR-Cas ribonucleoproteins in trans in a cell-  
319 targeted system (Rouet and Christ, 2019). Histidine residues have also been  
320 incorporated into previously described pore-forming peptides to improve their  
321 endosomolytic properties. In this regard, EB1 is a synthetic analog of penetratin in which  
322 certain residues have been substituted for histidines to yield an amphipathic alpha helix  
323 upon protonation at acidic pH (Lundberg et al., 2007).

324 Therefore, the use of histidine-rich peptides appears as a very promising strategy to  
325 induce the cytosolic release of targeted fusion proteins. In this regard, the major  
326 challenge related to the use of this type of EE peptides is determining the minimal  
327 amount of histidine residues that need to be incorporated to promote an effective  
328 proton sponge effect within the endosome.

### 329 **2.4 Protein translocation to the cytosol**

330 This particular EE mechanism has been mainly described in the diphtheria toxin (DT)  
331 from *Corynebacterium diphtheriae* (Ladokhin et al., 2021). DT is a potent toxin  
332 composed of three different domains including a receptor (R domain), a translocation (T  
333 domain) and a catalytic domain (C domain). Thus, the R domain serves as a ligand for  
334 the receptor-mediated endocytosis of the toxin. Then, a furin cleavable site located  
335 between the T and C domains, drives the separation of both domains at early  
336 endosomes, which remain attached through an intermolecular disulfide bond. Later, at

337 acidified endosomes, the T domain undergoes a conformational change that results in  
338 its endosomal membrane insertion, forming a small pore through which the C domain is  
339 specifically transported to the cytosol. There, the intermolecular disulfide bond is  
340 immediately cleaved by cytosolic thioredoxin reductase and the C domain is finally  
341 refolded back into its active conformation (assisted by cytosolic Hsp90 chaperone) to  
342 catalyze the ADP-ribosylation of the elongation factor 2 and promote cell death (Figure  
343 1D) (Schuster et al., 2017).

344 A similar strategy was reported for the anthrax toxin from *Bacillus anthracis*. However,  
345 here, the protective antigen (PA) is both the receptor-binding and the pore-forming  
346 subunit (Friebe et al., 2016). Thus, once internalized by receptor-mediated endocytosis,  
347 the PA undergoes a conformational change at early endosomes that leads to pore  
348 formation and subsequent translocation of the enzymatic subunits across the  
349 membrane (Friebe et al., 2016). In this regard, although PA has already served for the  
350 translocation of some proteins (Bachran et al., 2013; Liao et al., 2014), its use in a  
351 targeted setting is not indicated because the PA itself shares both, intrinsic cell-targeting  
352 and EE properties.

#### 353 *2.4.1 Diphtheria-toxin assisted translocation in endosomal escape*

354 Fused to the N-terminal catalytic domain of the toxin, several proteins of multiple sizes  
355 and structures including Sumo,  $\alpha$ -amylase or m-Cherry, have been efficiently delivered  
356 to the cytoplasm of cells, hijacking the translocation process of the toxin (Auger et al.,  
357 2015). However, this strategy requires the use of both T (21.6 kDa) and C (20.4 kDa)  
358 domains of the toxin in order to transport other accompanying proteins to the cytosol.

359 The T domain alone has also been reported to be sufficient to promote EE of targeted  
360 proteins (Gilyazova et al., 2006). Nonetheless, it is still unclear how the T domain might  
361 assist the translocation of other proteins in absence of their disulfide linking. In this  
362 regard, a small region of the catalytic domain that includes its target cysteine to allow  
363 the disulfide-bond formation has been also incorporated to some protein designs (Aullo  
364 et al., 1993). Going still further, direct disulfide-conjugation to the diphtheria T-domain  
365 has also allowed the successful cytosolic delivery of the catalytic domain from the toxin  
366 ricin (Sundan et al., 1982). However, a partial interference of the T Domain over the  
367 receptor-specificity of a tumor targeted oligomeric protein nanoparticle has been also  
368 recently reported (Voltà-Durán et al., 2022).

369 Therefore, the diphtheria toxin T domain appears as an attractive tool in targeted  
370 proteins delivery since it shows high protein specificity, exclusively transporting the  
371 tagged protein without disrupting endosomes. However, its potential interference over  
372 the cell-targeting of some protein constructs needs to be closely watched. Also, the  
373 minimal domain segment required for such process needs to be still fully determined  
374 and its potential immunogenicity, derived from its large size and bacterial origin, needs  
375 to be also addressed.

#### 376 **2.5 Lysosomal bypassing**

377 Some pathogens and many plant and bacterial toxins such as *Pseudomonas aeruginosa*  
378 exotoxin A, ricin, cholera toxin, Shiga toxin, pertussis toxin or cytolethal distending  
379 toxins, hijack the Endoplasmic Reticulum-Associated Degradation (ERAD) mechanism to  
380 reach the cell cytosol and avoid lysosomal degradation (Morito and Nagata, 2015;

381 Nowakowska-Gołacka et al., 2019). This protein clearance mechanism allows misfolded,  
382 misassembled, or metabolically regulated proteins to be specifically dislocated from the  
383 endothelial reticulum into the cytosol to be degraded. Thus, once internalized by  
384 receptor-mediated endocytosis, toxins are retrogradely transported to the endoplasmic  
385 reticulum (ER), where the enzymatically active subunit is disassembled from the  
386 holotoxin and delivered to the cytosol (Figure 1E) (Nowakowska-Gołacka et al., 2019). It  
387 is important to note that the process of retrograde transport, extraction from the ER  
388 and refolding in the cytosol is particular for each toxin and it involves complex  
389 procedures in which different receptors, chaperones and other proteins take part  
390 (Mantis, 2012; Sowa-Rogozińska et al., 2019; Tsai et al., 2001).

#### 391 *2.5.1 Lysosomal bypassing in endosomal escape*

392 Taking advantage of the ERAD pathway, some protein fragments from the above-  
393 mentioned toxins have been recently used to drive the lysosomal bypassing of cargo  
394 proteins. For example, the translocation domain of *P. aeruginosa* exotoxin A has allowed  
395 the cytosolic delivery of different proteins including GFP and monobodies (Mohammed  
396 et al., 2012; Schmit et al., 2019). However, there is still a need to understand which is  
397 the exact mechanism by which fused proteins are efficiently translocated from the ER  
398 to the cytosol and then properly refolded to avoid their degradation.

399 In an attempt to reduce the toxin segment needed for this process, a simpler approach  
400 that just includes the furin cleavable site (FCS) and the C-terminal signal tetrapeptide  
401 KDEL has been successfully used to induce the cytosolic delivery of CXCR4-targeted  
402 catalytic segment of exotoxin A and ricin toxin (Díaz et al., 2018; Sánchez-García et al.,  
403 2018). Of note, both constructions lacked the full translocation domain, but also, both  
404 toxins originally use the ERAD mechanism in their natural intoxication process (Inoue et  
405 al., 2011; Michalska and Wolf, 2015). Therefore, it is important to know if this simpler  
406 strategy can be transversally used for the lysosomal bypassing of other cargo proteins  
407 or is strictly restricted to specific toxins.

408 Taking all presented EE mechanisms into consideration, the stronger candidates to be  
409 potentially included in targeted delivery protein-based nanocarriers have been  
410 summarized in **Table 1**. Here, pore-forming peptides are presented as probably the less  
411 suitable candidates since their cell penetrating properties can strongly interfere with  
412 protein targeting. In consequence, just few engineered pH-sensitive analogs derived  
413 from antimicrobial peptides (Mellitin, Bombilitin V, LL-37) and especially the animal  
414 peptide Aurein 1.2 has raised interest for a targeted-delivery setting. Fusogenic peptides  
415 could represent a more sophisticated option since their pH-selective activity better  
416 restricts their fusogenic action to endosomes. Moreover, some of the candidates (DEN,  
417 preS2, B18) have already been validated in EGFR-targeted delivery approaches, and  
418 human-derived peptides have also been described (S19). Nevertheless, the precise  
419 mechanism by which peptides that promote membrane fusion are able to induce the  
420 transportation of proteins across the endosomal membrane is still unclear. Histidine-  
421 rich peptides are presented in this review as one of the most promising candidates for  
422 cell-targeted delivery settings. This is because the proton sponge effect is endosome-  
423 exclusive and although they display milder endosomolytic potency, they show no  
424 interference with extracellular protein targeting. Moreover, humanized candidates such  
425 as H5E (HEHEHEHE) have been also successfully developed (López-Laguna et al.,

426 2020). Finally, the use of particular fragments of toxin proteins for direct endosomal  
427 translocation (Diphtheria toxin T Domain) or lysosomal by-passing (Exotoxin A T Domain,  
428 FCS + KDEL) has raised substantial interest but also important concerns at the same time.  
429 In this sense, they appear as attractive strategies because of their high protein specificity  
430 and general compatibility with protein targeting. However, their exact mechanism of  
431 action is yet to be revealed and in some cases their use may be also restricted to certain  
432 proteins or show partial interferences with targeting. Additionally, toxin domains are  
433 generally large segments within bacterial proteins (up to 21 kDa). Thus, their potential  
434 immunogenicity requires proper assessment if they are to be used in a clinical setting.

435

### 436 **3. Analytical evaluation of the endosomal escape:**

437 Appropriate tools for EE evaluation are important to properly determine the adequate  
438 performance of the EE elements incorporated to drug delivery platforms. In this sense,  
439 many methodologies, based on diverse protein properties, have been proposed to  
440 follow-up their intracellular fate. In general, all these strategies can be classified in two  
441 main groups that include basic and more simple assays performed using artificial  
442 membranes (*ex cellulo*) or complete and more complex assays performed in real cells (*in*  
443 *cellulo*).

#### 444 **3.1 Ex cellulo assays**

445 Membrane models such as liposomes have been frequently used as a preliminary test  
446 for EE of peptides and protein domains. Although representing an easy model for  
447 membrane interaction studies, liposomes do not completely mimic endosomal  
448 membranes. In this sense, they lack protein content and lipid asymmetry, but more  
449 importantly, they also lack the cellular microenvironment. To improve their similarity,  
450 liposomes containing mixtures of zwitterionic 2-oleoyl-1-palmitoyl-sn-glycero-3-  
451 phosphocholine (POPC) and negatively charged phospholipids have been prepared  
452 (Akishiba et al., 2017; Madani et al., 2011). Among them, formulations that include the  
453 anionic lipid Bis(monoacylglycerol)phosphate (BMP) are frequent as working tools (Allen  
454 et al., 2019; Sudo et al., 2017; Yang et al., 2010) since this particular lipid is highly  
455 enriched in the intraluminal side components of late endosomes (Kobayashi et al.,  
456 2001). Related to that, pH is also an important parameter to be considered when trying  
457 to establish a liposome model, especially when testing EE proteins devoted to  
458 discriminate endosomes (acidic micro-environment) from extracellular membranes  
459 (neutral pHs). For that, liposomes are usually tested against the EE agent in a buffer at  
460 the selected pH. However, some authors have also elaborated a more sophisticated  
461 method where the EE molecule is encapsulated within a vesicle that is enriched with  
462 bacteriorhodopsin (Madani et al., 2011), a transmembrane protein that allows the  
463 control of intraluminal pH. Finally, other membrane models such as isolated endosomes  
464 (Ahmad et al., 2015; Evans et al., 2013; Liu et al., 2017; Prchla et al., 1995) or  
465 erythrocytes in hemolysis assay (Ahmad et al., 2015; Evans et al., 2013; Liu et al., 2017)  
466 are also usually used since they show higher similarity with the cellular environment.

467 Spectrofluorimetry is one of the preferred technologies for the *ex cellulo* evaluation of  
468 pore-forming and fusogenic EE peptides (Martens et al., 2014; Selby et al., 2017). This  
469 methodology generally relies on the encapsulation of a quenched fluorophore within a

470 liposome, being then released upon the action of the EE promoter. Here we can  
471 distinguish between the use of self-quenched tracers such as calcein (Ahmad et al.,  
472 2015; Oude Blenke et al., 2017; Plaza-GA et al., 2019), sulforhodamine B (Burks et al.,  
473 2015) or carboxyfluorescein (Kakimoto et al., 2009) from the co-encapsulation of  
474 fluorophore/quencher pairs such as ANTS/DPX (8-Aminonaphthalene-1,3,6-trisulfonic  
475 acid disodium salt/p-xylene-bis-pyridinium bromide) (Akishiba et al., 2017; Yang et al.,  
476 2010) or HPTS/DPX (8-Hydroxypyrene-1,3,6-trisulfonic acid trisodium salt/p-xylene-bis-  
477 pyridinium bromide) (Yang et al., 2010). In both cases, the release of encapsulated  
478 fluorophores and their subsequent dilution in the media results in a reduced quenching  
479 activity and consequent increase of fluorescence, which is easily detected in a  
480 spectrofluorometer. Although this methodology provides relevant data about the  
481 membrane integrity of liposomes and the permeability of small molecules, it does not  
482 necessarily predict their capacity to release larger molecules such as proteins (Smith et  
483 al., 2019). To overcome this limitation, alternative approaches for the direct detection  
484 of encapsulated proteins have also been proposed. In this regard, radiolabeled proteins  
485 (van Rossenberg et al., 2002) or fluorescent-labelled proteins (encapsulated with their  
486 quencher) (Madani et al., 2013) can be directly detected in the extra-liposomal media  
487 by agarose gel electrophoresis or spectrofluorimetry, respectively.

488 In general, experiments with membrane models represent a simple and efficient tool for  
489 the EE evaluation of fusogenic or pore-forming candidates. However, they show  
490 important limitations when dealing with more complex mechanisms such as the proton  
491 sponge effect, the direct translocation, or the retrograde transport, which require the  
492 cellular microenvironment and intracellular trafficking machinery. Because of this,  
493 several *in cellulo* evaluation methods have been developed.

### 494 **3.2 *In cellulo* assays**

495 Two important considerations are needed when designing EE evaluation methods using  
496 living cells (*in cellulo*). First, a precise comprehension of the information that can be  
497 extracted from each particular technique is required. Second, different approaches must  
498 be usually combined in order to allow a precise and reliable interpretation of the  
499 obtained data (Selby et al., 2017).

#### 500 3.2.1 Fluorescence measurement:

501 Fluorescence evaluation, generally based on flow cytometry or fluorescence  
502 microscopy, is the most common way to detect EE (Martens et al., 2014). In this sense,  
503 flow cytometry provides high-throughput and quantitative data about the total  
504 fluorescence intensity within cells. On the other hand, fluorescence microscopy and  
505 especially confocal laser microscopy provide qualitative data about the intracellular  
506 localization of this signal, also known as intracellular fluorescence pattern (IFP)  
507 (Salomone et al., 2012). Thus, a diffuse fluorescence signal within the cytoplasm would  
508 be indicative of a cytosolic distribution, while a dotted signal, would suggest an  
509 entrapped fluorophore (probably into endo-lysosomes). Therefore, the combination of  
510 both methodologies, flow cytometry and IFP analysis, represents a potent tool for EE  
511 evaluation.

512

513 *3.2.1.1 Independent fluorescent tracers:*

514 The use of self-quenched tracers is an extended method for the evaluation of endosomal  
515 membrane integrity, as seen in *ex cellulo* approaches. In this sense, calcein is a widely  
516 used membrane-impermeable fluorophore that is loaded into endosomes by passive  
517 micropinocytosis (Smith et al., 2019). Calcein is weakly fluorescent inside the  
518 endosomes due to its self-quenching activity and low pH. Thus, when endosomes are  
519 disrupted, the release and consequent dilution of calcein into the cytosol results in an  
520 increase of fluorescence (Hu et al., 2007; Kim et al., 2018; J.-S. Kim et al., 2016; Salomone  
521 et al., 2012; Wong et al., 2015) (Figure 2A). In a similar approach, acridine orange (AO),  
522 forms red fluorescent dimers at high concentrations and acidic environment. Then, it  
523 shifts to green fluorescence when released into the cytosol (Kandil et al., 2019) (Figure  
524 2B).

525 This kind of tracers have been proven very useful in the evaluation of endosomal  
526 permeability to small molecules but have shown some limitation when dealing with  
527 proteins. In this regard, an alternative approach takes advantage of the lysosomal  
528 degradation of DQ-ovalbumin, a high MW protein (45 KDa) conjugated with a self-  
529 quenched green fluorescent tracer. Here, the self-quenched tracer becomes highly  
530 fluorescent upon protein degradation in lysosomes (Quarta et al., 2017) (Figure 2C).  
531 Thus, in this innovative approach, the absence of fluorescence signal directly correlates  
532 with protein release.

533 *3.2.1.2 Direct protein detection:*

534 Not all the analytical strategies are based on the indirect detection of independent  
535 tracers. Some methods directly track the intracellular fate of proteins through their  
536 intrinsic fluorescence (Auger et al., 2015; Niikura et al., 2015; Sánchez-García et al.,  
537 2017; Sudo et al., 2017) or by labelling them with a fluorescent tracer (Ahmed et al.,  
538 2016; A. Kim et al., 2016; Mellert et al., 2012). Here, fluorescence microscopy is the  
539 preferred tool, allowing the qualitative evaluation of IFP (Figure 2D). Some protocols,  
540 however, have also tried to establish a quantitative evaluation of IFP using microscopy.  
541 For that, they measure the median fluorescence value (Mellert et al., 2012) or the  
542 absolute fluorescence value at determined regions of interest (Basha et al., 2011). Going  
543 still further, Lee et al. reported an innovative approach based on a fluorescence  
544 resonance energy transfer (FRET) assay. For that, a green fluorescent tracer with  
545 capacity to perform FRET was attached to mCherry together with its quencher molecule,  
546 the last one attached by a disulfide bond. Thus, in case of EE, the disulfide bond is  
547 reduced into the cytosol and the quencher molecule released. In consequence, upon  
548 excitation of the green tracer, fluorescent energy is transferred to mCherry (FRET) and  
549 red fluorescence is detected into the cytosol (Lee et al., 2008) (Figure 2E).

550 *3.2.1.3 Co-localization studies:*

551 The use of fluorescent labels, usually highly hydrophobic, have raised some concerns  
552 when dealing with direct protein tracking since they can interfere with the EE process  
553 (Mellert et al., 2012). Similarly, the use of acidotropic dye molecules such as  
554 LysoTracker® or LysoView®, which are widely used in organelle co-localization studies  
555 (Ahmed et al., 2016; Allen et al., 2019; J.-S. Kim et al., 2016; Lieser et al., 2022; Sakurai  
556 et al., 2011), might influence the acidification process of endosomes due to their weakly

557 basic nature (Selby et al., 2017). The use of such molecules can be avoided by the direct  
558 detection of lysosomal-associated membrane proteins such as LAMP-1 by  
559 immunostaining (Basha et al., 2011; J.-S. Kim et al., 2016; Wensley et al., 2020) or by its  
560 genetic fusion with a fluorescent protein (Allen et al., 2019; Wong et al., 2015). The  
561 lysosomal protein LAMP-2 (Huang et al., 2010) or the endosomal protein EEA1 (Huang  
562 et al., 2010; Wensley et al., 2020) have been also used in this regard. Altogether,  
563 although co-localization studies are mainly qualitative, some efforts have been done  
564 towards turning them quantitative (Bolte and Cordelières, 2006; Vercauteren et al.,  
565 2011).

#### 566 *3.2.1.4 Fluorescence accumulation pattern:*

567 Flow cytometry is the quantitative partner of fluorescence microscopy. Here, the  
568 intracellular accumulation of fluorescent proteins, in combination with endosomal  
569 maturation inhibitors such as chloroquine, has served as a lysosomal degradation  
570 indicator. Thus, a larger increase of intracellular fluorescence in presence of chloroquine  
571 has been correlated with a lower ability of EE (López-Laguna et al., 2020; Sánchez-García  
572 et al., 2017; Serna et al., 2019). However, the use of chloroquine is still controversial  
573 since its precise role in EE is unclear yet (Hajimolaali et al., 2021; Wensley et al., 2020).  
574 Alternatively, other endosomal acidification blockers such as the v-type proton-pump  
575 ATPase inhibitor Bafilomycin A1 have been also applied in the same sense (Martens et  
576 al., 2014).

577 Recently, an innovative flow cytometry methodology based on the pulse shape analysis  
578 of accumulated fluorescent signal has been proposed (Wensley et al., 2020). In this  
579 approach, when the fluorescence homogeneously distributes in the cytosol (endosomal  
580 escape), the width of the pulse signal increases. In contrast, when the fluorescence is  
581 trapped into the endosomes (dotted pattern), the height of the pulse signal increases  
582 while the width decreases. This assay was found to be more sensitive than confocal  
583 microscopy and represents an elegant tool for EE quantification of fluorescent proteins.

#### 584 *3.2.1.5 Protein complementation assays:*

585 Protein complementation assays are also very useful for EE evaluation in fluorescent  
586 proteins. In such assays, one region of the fluorescent protein is constitutively expressed  
587 in the cytosol of the target cell. Then, the other complementing region is extracellularly  
588 administered in form of a fusion protein that include the EE enhancer and the targeting  
589 moiety for cell internalization. Thus, in case of efficient EE, the full protein is re-  
590 assembled into the cytosol and restores its fluorescence (Figure 2F). In this regard, GFP-  
591 complementation has been the most explored strategy (Kim et al., 2018, 2015; Lönn et  
592 al., 2016).

#### 593 3.2.2 Biological activity measurements:

594 Measuring the action of specific proteins that perform their biological activity into the  
595 cytosol or other subcellular organelles can be also an indirect way to evaluate their EE  
596 (Figure 3A). However, it is important to note that this process is highly dependent on  
597 the intracellular trafficking of particular cell lines or types, which can somehow narrow  
598 the transversal value of data interpretation (Deprey et al., 2019). Thus, the detection of  
599 apoptosis-associated markers is frequently used when studying the action of proteins

600 with cytotoxic activity such as targeted toxins or proapoptotic proteins (Díaz et al., 2018;  
601 Hetzel et al., 2008; Kiesgen et al., 2014; Wensley et al., 2020). Other approaches  
602 combine EE peptides with enzymes such as  $\alpha$ -amylase (Auger et al., 2015),  $\beta$ -  
603 galactosidase (Maier et al., 2012), luciferase (Jiang et al., 2020) or  $\beta$ -lactamase (Garcia-  
604 Castillo et al., 2015) that show easily measurable enzymatic activities into the cytosol.  
605 Another more sophisticated method measures the cytosolic activity of Cre recombinase  
606 in a cell line that has been previously transfected with a plasmid susceptible of gene  
607 recombination. Thus, if EE takes place, Cre recombinase promotes the recombination  
608 event, which can then be measured through the expression and activity of the encoded  
609 reporter protein (Akishiba et al., 2017; Li et al., 2015; Wadia et al., 2004) . The use of  
610 antigens and the subsequent analysis of the immune response by assessing the  
611 production of IL-2 (Yuba et al., 2010) or MHC I presentation kinetics (Vasdekis et al.,  
612 2012) have also served as a proof of cytosolic delivery.

613 Finally, the EE of targeted proteins has been also evaluated by measuring the biological  
614 activity of a cargo nucleic acid in the target cell. However, the need of reaching the cell  
615 nucleus when transporting DNA introduces an additional barrier that significantly  
616 complicates the interpretation of data resulting from this approach (Selby et al., 2017).  
617 To avoid this problem, the delivery of cargo siRNAs for endogenous (e.g. syntaxin 5)  
618 (Dyer et al., 2015) or reporter (e.g. luciferase) (Hatakeyama et al., 2009; Sakurai et al.,  
619 2011) gene knockdown have been more extensively used, as they directly perform their  
620 action in the cytosol. Still, this methodology may present some important limitations  
621 such as RNA degradation or intracellular dissociation during the process.

### 622 3.2.3 Cellular fractionation:

623 Cellular fractionation and subsequent protein localization is a very interesting approach  
624 for EE evaluation. Although this methodology has mainly been explored for subcellular  
625 localization of nucleic acids using qPCR (Akita et al., 2004; Hama et al., 2006), its basis  
626 can also be applied to protein localization assays via fluorescence measurements or  
627 Western Blot immunodetection (Lee et al., 2010; Niikura et al., 2016) (Figure 3B). The  
628 major advantage of this particular approach relays in its suitability for *in vivo* EE  
629 determination, as cellular fractionation can also be performed from tissue lysates  
630 (Richardson et al., 2010). Nevertheless, the methodology is laborious and cross-  
631 contamination between different subcellular fractions must be prevented during the  
632 process (Lee et al., 2010).

### 633 3.2.4 Cytosolic enzyme modifications:

634 Several research groups have evaluated the EE of proteins by measuring specific  
635 modifications generated into the cytosol by endogenous (farnesyltransferase, de-  
636 ubiquitinase) (Falnes et al., 1995; Loison et al., 2005), or recombinant ( $\beta$ -galactosidase  
637 or Biotin ligase) (Chao and Raines, 2013; Verdurmen et al., 2017) enzymes. These  
638 modifications, that usually result in a change in the protein molecular weight, are easily  
639 detected by SDS-PAGE or Western Blot (Figure 3C). Although these approaches are  
640 versatile and compartment-specific, the addition of tags in the protein sequence may  
641 potentially affect their behavior or generate artifacts due to protein degradation (Serna  
642 et al., 2019).

643



### 644 3.2.5 Electron microscopy:

645 Visualization through electron microscopy has been proved useful for the localization of  
646 intracellular inorganic particles, which showing high electrodensity, require no labelling  
647 for detection (Martens et al., 2014). However, this methodology appears to be more  
648 challenging when dealing with protein materials or reporter proteins, since their low  
649 electrodensity prevents their easy distinction from other subcellular structures and  
650 proteins. In this regard, the subcellular localization of specific proteins can be easily  
651 detected in electron microscopy by immunogold approaches (gold-labeled protein-  
652 specific antibodies) (Chanoca and Otegui, 2014; Guzmán et al., 2010; Peters et al., 2006,  
653 1991)(Figure 3D).

654 Altogether, many different strategies have been developed for EE evaluation, being *in*  
655 *cellulo* assays the ones providing the most accurate information about specific proteins  
656 intracellular localization. However, an adequate combination of these approaches is still  
657 recommended to overcome the main drawback presented in each method. In this  
658 regard, different *in cellulo* methods have been summarized in **Table 2**, making emphasis  
659 in their key advantages and major drawbacks. It is important to note that strategies  
660 requiring protein labeling are the ones raising most important concerns regarding  
661 targeted proteins, as the labeling could potentially interfere with protein targeting and  
662 its subsequent intracellular trafficking.

663

## 664 **4. Future perspectives**

665 Poor or moderate EE is a main bottleneck in receptor-mediated drug delivery, especially  
666 when the drug and/or the cargo are protein-based. The rapidly increasing number of  
667 protein drugs, protein-based cell-targeting agents and protein materials used as carriers,  
668 combined with the urgent need of receptor-targeted medicines make this limitation,  
669 long time neglected, very evident. Then, while the catalogue of specific ligands or cell  
670 surface receptors is increasing, the number of EE protein agents remains limited. More  
671 importantly, their mechanisms of actions are diverse, controversial and in general poorly  
672 understood. Therefore, the mere incorporation of any among of such agents to a protein  
673 drug or carrier does not guarantee a significant increase in the cytoplasmic release of  
674 active molecules. Importantly, the background cell penetrating activities of some of the  
675 suspected EE peptides might interfere with the receptor-targeting agents present in the  
676 protein-drug nanomedicine. Because of the relevance of specific cell-targeting,  
677 especially in oncology but also in other applications of precision nanomedicines, the  
678 potential loss of specificity should be a matter of attention when designing a  
679 multifunctional construct with EE activities. In fact, the progressive elucidation of the EE  
680 mechanics for specific peptides combined with a detailed design and tailoring of the  
681 protein constructs is expected to provide highly selective drugs with relevant endosomal  
682 escape abilities.

683 In this context, methodologies and approaches to finely analyze EE emerge as new and  
684 extremely valuable tools, necessary for a proper functional design of drugs for  
685 cytoplasmic activities. Despite the intrinsic complexity of the EE determination, since it  
686 involves procedures that interfere with the cell biology, enormous advances in the field  
687 are paving the way for a better comprehension of the diversity of EE mechanisms, and

688 for their functional and structural adaptation to specific drug delivery platforms.  
689 Effective nanoscale carriers that combine high receptor targeting and efficient  
690 endosomal escape are expected to be developed in the next years. This will allow a  
691 quantitative and significant jump in the effectiveness and performance of protein-based  
692 drugs. After 40 years of recombinant protein drug production, the design of a new  
693 generation of highly efficient biopharmaceuticals should finally fulfill the current,  
694 pushing and unpostponable demands of innovative medicine.

695

696

697

698

699

700

701

702 **Table 1. EE agents with potential interest in targeted delivery approaches**

703

	<b>Amino acid sequence</b>	<b>Origin</b>	<b>Specificity mechanism</b>	<b>Cis delivery tested</b>	<b>Targeted delivery tested</b>	<b>Refs</b>
<b>Pore-forming peptides</b>						
Mellitin analogue	CGIGAVLEVLTTGLPALISWIEEEQQ	Animal*	CC at acidic pH	No	No	(Ahmad et al., 2015)
Bombollitin V analogue	CINVLGILGLLGEALSEL	Animal*	CC at acidic pH	No	No	(Ahmad et al., 2015)
LL-37 analogue	CLLGDFFESEEEIIGEEFEEIVQEIEDFLE NLVPETES	Human*	CC at acidic pH	No	No	(Ahmad et al., 2015)
LZEP	CLELLEELLELLELLELLEEL	Synthetic	CC at acidic pH	No	No	(Ahmad et al., 2021)
Aurein 1.2	GLFDIIKKIAESF	Animal	Affinity for AL	Yes	Yes	(Li et al., 2015; Lieser et al., 2022)
<b>Fusogenic peptides</b>						
INF-7	GLFEAIEGFIENGWEGMIWDYG	Synthetic	CC at acidic pH	Yes	Yes	(Lin et al., 2014; Liu et al., 2017; Sung et al., 2013)
GALA3	LAEALAEALEALAA	Synthetic	CC at acidic pH	Yes	No	(Li et al., 2020)
Pre-S2 domain	PLSSIFSRIGDP	Viral	Unclear	Yes	Yes	(Fuchs et al., 2007; Oess and Hildt, 2000)
DEN	MVDRGWGNGCGLFGKGGIV	Viral	CC at acidic pH + affinity for AL	Yes	Yes	(Kiesgen et al., 2014)
B18	PYDLGLLLRHLRHHSNLLANI	Animal	Unclear	Yes	Yes	(Niikura et al., 2016, 2015)
S19	PFVIGAGVLGALGTGIGGI	Human	Affinity for LE membranes	Yes	No	(Sudo et al., 2017)
<b>Histidine-rich peptides</b>						
Polyhistidine tags	HHHHHH HHHHHHHH HHHHHHHHHH	Synthetic	Protonation at acidic pH	Yes	Yes	(Dhankher et al., 2021)
Humanized histidine tags	HAAHAH HTHTHTHTH HEHEHEHEH	Human*	Protonation at acidic pH	Yes	Yes	(López-Laguna et al., 2020)

ppTG21	GLFHALLHLLHSLWLLLLHA	Synthetic	Protonation at acidic pH	No	Yes	(Rouet and Christ, 2019)
<b>Toxins-derived peptides</b>						
Diphtheria toxin T domain	<b>GNRVRRSV</b> GSSLSCLNDWDVIRDKTK TKIESLKEHGPIKNKMSESPNKTVSEEK AKQYLEEFHQTALEHPELSELKTVTGT NPVFAGANYAAWAVNVAQVIDSETA DNLEKTTAALSILPGIGSVMGIADGAV HHNTEEIVAQSIALSSLMVAQAIPLVG ELVDIGFAAYNFVESIINLFQVVHNSYN RPAYSPGHKT	Bacterial	CC at acidic pH	Yes	Yes	(Gilyazova et al., 2006)
Diphtheria toxin C domain C-ter region + T domain	GQDAMYEYMAQACAG <b>GNRVRRSV</b> GS SLSCINLDWDVIRDKTKTKIESLKEHGPI KNKMSESPNKTVSEEKAKQYLEEFHQTA ALEHPELSELKTVTGTNPVFAGANYAA WAVNVAQVIDSETADNLEKTTAALSIL PGIGSVMGIADGAVHHNTEEIVAQSIA LSSLMVAQAIPLVGELVDIGFAAYNFV ESIINLFQVVHNSYNRPAYSPGHKT	Bacterial	CC at acidic pH	Yes	No	(Aullo et al., 1993)
Exotoxin A T domain	GGSLAALTAHQACHLPLETFT <b>RHRQP</b> <b>RGWEQLE</b> QCGYPVQRLVALYLAARLS WNQVDQVIRNALASPGSGDLGEAIR EQPEQARLALTLAAAESERFVRQGTG NDEAGAAANADVSLTCPVAAGECAG PADSGDALLERNYPTGAEFLGDGGDV SFSTR	Bacterial	ERAD pathway	Yes	Yes	(Mohammed et al., 2012; Schmit et al., 2019)
Exotoxin A FCS + KDEL	<b>GNRVRRSV</b> + cargo + C-terminal KDEL	Bacterial	ERAD pathway	Yes	Yes	(Díaz et al., 2018)

704

705 \* Modified from the original sequence

706 CC: Conformational Change.

707 LE: Late Endosomes

708 AL: Anionic Lipids

709 Furin cleavable sites (FCS) have been highlighted in bold

710 **Table 2. *In celulo* methods for EE evaluation**

Category	Subcategory	Technique	Key advantages	Major drawbacks	Ref
<b>Fluorescence measurements</b> Detection by fluorescence microscopy (mostly qualitative) and/or flow cytometry (mostly quantitative)	Require the use of tracers	<b>Calcein leakage assay</b>	Easy pH-specific	Possibility of false positives due to membrane destabilization Not useful for translocations	(Kim et al., 2018; J.-S. Kim et al., 2016; Salomone et al., 2012; Wong et al., 2015)
		<b>Acridine orange assay</b>	Easy pH-specific	Tracer may affect endosomal maturation process Possibility of false positives due to membrane destabilization Not useful for translocations	(Kandil et al., 2019)
		<b>DQ-ovalbumin assay</b>	Measures degradation Measures protein escape	Labelling requirement Not useful for translocations	(Quarta et al., 2017)
		<b>Co-localization studies with tracers</b>	pH-specific Useful for all mechanisms	Tracers may affect endosomal maturation process High-levels of background Difficult to quantify	(Ahmed et al., 2016; Allen et al., 2019; J.-S. Kim et al., 2016; Sakurai et al., 2011; Selby et al., 2017)
	Requires the use of inherent fluorescent proteins or fluorophore-conjugated proteins	<b>Co-localization studies in stable cell lines</b>	pH-specific Useful for all mechanisms	Requires stable cell line expressing exogenous gene Difficult to quantify	(Allen et al., 2019; Huang et al., 2010; J.-S. Kim et al., 2016; Wensley et al., 2020)
		<b>Cytosolic specific FRET</b>	Measures protein escape Cytosolic specific Useful for all mechanisms	Double labelling requirement Possibility of false positives due to spontaneous reduction of S-S bond Possibility of false negatives due to spontaneous unlabelling	(Lee et al., 2008)
		<b>Fluorescence accumulation pattern</b>	Easy Useful for all mechanisms	Possibility of false negatives due to fluorophore dilution Controversy in the use of some agents	(López-Laguna et al., 2020; Sánchez-García et al., 2017; Serna et al., 2019)
		<b>Pulse-shape analysis</b>	Easy Useful for all mechanisms Do not rely on the use of any additional compound Higher sensibility than confocal microscopy	More data is required Endosomal distribution in used cell line affects the sensibility	(Wensley et al., 2020)
		<b>Complementation assay</b>	Useful for all mechanisms Do not rely on the use of any additional compound No labelling	Requires stable cell line expressing exogenous gene	(Kim et al., 2018, 2015; Lönn et al., 2016)
				Subunits must find each other in the cytosol	
<b>Biological activity measurements</b>	Measure the activity of proteins	<b>Cell viability assay</b>	Easy Applicable to therapeutic candidates Useful for all mechanisms No labelling High sensibility Compartment-specific	Possibility of false negatives due to subsequent protein trafficking Possibility of false negatives due to the effect of endosomal escape promoter to the protein	(Díaz et al., 2018; Hetzel et al., 2008; Kiesgen et al., 2014; Wensley et al., 2020)

		<b>Enzymatic assays</b>	Applicable to therapeutic candidates Useful for all mechanisms No labelling Compartment-specific	Possibility of false negatives due to subsequent protein trafficking Possibility of false negatives due to the effect of endosomal escape promoter to the protein	(Auger et al., 2015; Garcia-Castillo et al., 2015; Jiang et al., 2020; Maier et al., 2012)
		<b>Immunologic assays</b>	Applicable to therapeutic candidates Useful for all mechanisms No labelling Compartment-specific	Possibility of false negatives due to subsequent protein trafficking	(Vasdekis et al., 2012; Yuba et al., 2010)
	Measure the activity of nucleic acids	<b>Gene silencing assays</b>	Applicable to therapeutic candidates Cytosolic specific Useful for all mechanisms	Possibility of false negatives due to subsequent cargo trafficking RNA labelling requirement For silencing exogenous genes, it requires stable cell line expressing exogenous gene	(Dyer et al., 2015; Hatakeyama et al., 2009; Sakurai et al., 2011)
<b>Cellular fractionation</b>	Measure protein	<b>Fluorescence measurements or Western Blot</b>	Suitable for <i>in vivo</i> assays No labelling Useful for all mechanisms	Labor-intensiveness Risk of contamination between subcellular locations Macromolecules may alter vesicle density	(Lee et al., 2010; Niikura et al., 2016)
	Measure nucleic acids	<b>qPCR</b>	Suitable for <i>in vivo</i> assays Useful for all mechanisms	Labor-intensiveness Risk of contamination between subcellular locations Macromolecules may alter vesicle density Labelling requirement	(Akita et al., 2004; Hama et al., 2006)
<b>Cytosolic enzyme modifications</b>	Require expression of exogenous enzymes	<b>Beta-galactosidase and biotin ligase assay</b>	Cytosolic specific Useful for all mechanisms	Requires stable cell line expressing exogenous gene Labelling requirement	(Chao and Raines, 2013; Verdurmen et al., 2017)
	Do not require the expression of exogenous enzymes	<b>Farnesylation assay</b>	Cytosolic specific Useful for all mechanisms	Requires subsequent cellular treatment CaaX motif C-ter might promote protein cytosolic degradation	(Falnes et al., 1995)
		<b>De-ubiquitination assay</b>	Cytosolic specific Useful for all mechanisms	Requires subsequent cellular treatment Labelling requirement	(Loison et al., 2005)
<b>Electron microscopy</b>		<b>Immuno-TEM</b>	Compartment-specific Direct visualization Useful for all mechanisms	Cell fixation requirement Labelling requirement	(Chanoca and Otegui, 2014; Guzmán et al., 2010; Peters et al., 2006, 1991)

712 **Figure Captions:**

713 **Figure 1. Endosomal escape mechanisms.** A. Pore-forming peptides can create channels in  
714 endosomes membranes following the barrel-stave (i), carpet (ii) or toroidal (iii) models. B. Viral  
715 fusogenic peptides (in blue) drive the fusion between viral and endosomal membranes due to a  
716 pH-dependent conformation change that induce their insertion into the endosomal membranes.  
717 C. Histidine-rich peptides in proteins (in red) become protonated at acidic pH. This fact promotes  
718 the entrance of protons (in yellow) in the endosomal lumen, which is followed by an entrance  
719 of chloride ions (in green) to compensate charges. The consequent increase in the osmotic  
720 pressure ends up in endosome lysis and in the release of its content to the cytosol (proton  
721 sponge effect). D. Direct protein translocation from the endosome lumen to the cytosol  
722 mediated by a toxin translocation domain (in yellow). A pH-mediated conformational  
723 rearrangement of the translocation domain initiates this process at late-endosomes. E.  
724 Lysosomal bypassing of proteins (in blue) following the ERAD recycling pathway. Specific toxin  
725 translocation domains drive the cargo protein to the endoplasmic reticulum, by which they are  
726 retrogradely transported to the cytosol. E: Endosome, L: Lysosome, ER: Endoplasmatic  
727 Reticulum.

728

729 **Figure 2. Fluorescence based methods:** A. Endosomal escape evaluation via self-quenched  
730 fluorescent tracers such as calcein. Endosomal disruption dilutes the fluorophore into the  
731 cytoplasm ending its quenching and triggering an increase in green fluorescence. B. Acridine  
732 orange is used similarly to calcein to detect endosomal escape. However, in acidic endosomes it  
733 assumes the form of red-fluorescent dimers, allowing a clear differentiation of endosomal  
734 entrapment or escape situations. C. Use of DQ-ovoalbumin, a self-quenched fluorogenic  
735 substrate for proteases that emits a strong fluorescent signal upon degradation to small labelled  
736 peptides inside the lysosome. D. Use of labelled or intrinsically fluorescent proteins to directly  
737 evaluate their endosomal fate via fluorescence microscopy. E. Use of a quenched FRET-  
738 dependent fluorescent protein that emits red fluorescence upon release into the cytosol from  
739 the endosomes. Reduction of the disulfide-bound quencher allows the green fluorescent moiety  
740 to excite the red fluorophore. F. Protein complementation assay where the endosomal escape  
741 peptide is fused to the complementing domain of a cytosol-expressed truncated fluorescent  
742 protein. When endosomal escape occurs, the truncated protein in the cytosol is complimented,  
743 restoring its fluorescence emission.

744

745 **Figure 3. Other analytical methods:** A. Overview of the main detection systems to evaluate  
746 endosomal escape based on biological functions or the alteration of these. B. Subcellular  
747 fractionation and subsequent antigenic or fluorescence detection in order to elucidate the fate  
748 of a given protein candidate with an endosomal escape domain. C. Endosomal escape is  
749 evaluated via determination of the candidate protein molecular weight. The studied protein is  
750 susceptible to cytosolic modifications that can increase or decrease its mass. D. Use of electron  
751 microscopy combined with gold immunolabeling to explore the subcellular location of the  
752 protein of interest.

753

754

755



756 **Acknowledgements:**

757 The authors are indebted to Agencia Española de Investigación for granting projects on  
758 the construction of protein materials of clinical interest (PID2019-105416RB-  
759 I00/AEI/10.13039/501100011033 to EV and PID2020-116174RB-I00 to AV), to AGAUR  
760 for project 2017 SGR- 229 to AV, and to ISCIII for project PI20/00400 to UU co-funded  
761 by European Regional Development Fund (ERDF, “a way to make Europe”). We also  
762 appreciate the funding from the CIBER -Consortio Centro de Investigación Biomédica en  
763 Red- (CB06/01/0014), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación,  
764 through projects (Nanoremove, Nanopills, Venom4Cancer, Nanoprother II, Nanoscape  
765 and Nanolink). U.U. was supported by a Miguel Servet contract (CP19/00028) from ISCIII  
766 co-funded by European Social Fund (ESF investing in your future). E.V-D was supported  
767 by a predoctoral fellowship from Ministerio de Ciencia, Innovación y Universidades  
768 (FPU18/04615). A.V. received an ICREA ACADEMIA award.

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784 **References:**

- 785 Ahmad, A., Khan, J.M., Haque, S., 2019. Strategies in the design of endosomolytic agents for  
786 facilitating endosomal escape in nanoparticles. *Biochimie* 160, 61–75.  
787 <https://doi.org/10.1016/j.biochi.2019.02.012>
- 788 Ahmad, A., Ranjan, S., Zhang, W., Zou, J., Pyykkö, I., Kinnunen, P.K.J., 2015. Novel  
789 endosomolytic peptides for enhancing gene delivery in nanoparticles. *Biochimica et*  
790 *Biophysica Acta (BBA) - Biomembranes* 1848, 544–553.  
791 <https://doi.org/10.1016/j.bbamem.2014.11.008>
- 792 Ahmad, A., Rilla, K., Zou, J., Zhang, W., Pyykkö, I., Kinnunen, P., Ranjan, S., 2021. Enhanced  
793 gene expression by a novel designed leucine zipper endosomolytic peptide. *Int J Pharm*  
794 601, 120556. <https://doi.org/10.1016/j.ijpharm.2021.120556>
- 795 Ahmed, S., Fujita, S., Matsumura, K., 2016. Enhanced protein internalization and efficient  
796 endosomal escape using polyampholyte-modified liposomes and freeze concentration.  
797 *Nanoscale* 8, 15888–15901. <https://doi.org/10.1039/C6NR03940E>
- 798 Akishiba, M., Takeuchi, T., Kawaguchi, Y., Sakamoto, K., Yu, H.-H., Nakase, I., Takatani-Nakase,  
799 T., Madani, F., Gräslund, A., Futaki, S., 2017. Cytosolic antibody delivery by lipid-sensitive  
800 endosomolytic peptide. *Nat Chem* 9, 751–761. <https://doi.org/10.1038/nchem.2779>
- 801 Akita, H., Ito, R., Khalil, I.A., Futaki, S., Harashima, H., 2004. Quantitative Three-Dimensional  
802 Analysis of the Intracellular Trafficking of Plasmid DNA Transfected by a Nonviral Gene  
803 Delivery System Using Confocal Laser Scanning Microscopy. *Molecular Therapy* 9, 443–  
804 451. <https://doi.org/10.1016/j.ymthe.2004.01.005>
- 805 Allen, J., Brock, D., Kondow-McConaghy, H., Pellois, J.-P., 2018. Efficient Delivery of  
806 Macromolecules into Human Cells by Improving the Endosomal Escape Activity of Cell-  
807 Penetrating Peptides: Lessons Learned from dfTAT and its Analogs. *Biomolecules* 8, 50.  
808 <https://doi.org/10.3390/biom8030050>
- 809 Allen, J., Najjar, K., Erazo-Oliveras, A., Kondow-McConaghy, H.M., Brock, D.J., Graham, K.,  
810 Hager, E.C., Marschall, A.L.J., Dübel, S., Juliano, R.L., Pellois, J.-P., 2019. Cytosolic Delivery  
811 of Macromolecules in Live Human Cells Using the Combined Endosomal Escape Activities  
812 of a Small Molecule and Cell Penetrating Peptides. *ACS Chem Biol* 14, 2641–2651.  
813 <https://doi.org/10.1021/acscchembio.9b00585>
- 814 Auger, A., Park, M., Nitschke, F., Minassian, L.M., Beilhartz, G.L., Minassian, B.A., Melnyk, R.A.,  
815 2015. Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a  
816 Bacterial Toxin. *Mol Pharm* 12, 2962–2971.  
817 <https://doi.org/10.1021/acs.molpharmaceut.5b00233>
- 818 Aullo, P., Giry, M., Olsnes, S., Popoff, M.R., Kocks, C., Boquet, P., 1993. A chimeric toxin to  
819 study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament  
820 assembly. *EMBO J* 12, 921–931. <https://doi.org/10.1002/j.1460-2075.1993.tb05733.x>
- 821 Bachran, C., Morley, T., Abdelazim, S., Fattah, R.J., Liu, S., Leppla, S.H., 2013. Anthrax Toxin-  
822 Mediated Delivery of the *Pseudomonas* Exotoxin A Enzymatic Domain to the Cytosol of  
823 Tumor Cells via Cleavable Ubiquitin Fusions. *mBio* 4.  
824 <https://doi.org/10.1128/mBio.00201-13>

- 825 BAREFORD, L., SWAAN, P., 2007. Endocytic mechanisms for targeted drug delivery☆. *Adv Drug*  
826 *Deliv Rev* 59, 748–758. <https://doi.org/10.1016/j.addr.2007.06.008>
- 827 Basha, G., Novobrantseva, T.I., Rosin, N., Tam, Y.Y.C., Hafez, I.M., Wong, M.K., Sugo, T., Ruda,  
828 V.M., Qin, J., Klebanov, B., Ciufolini, M., Akinc, A., Tam, Y.K., Hope, M.J., Cullis, P.R., 2011.  
829 Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid  
830 Nanoparticle Formulations of siRNA in Antigen-Presenting Cells. *Molecular Therapy* 19,  
831 2186–2200. <https://doi.org/10.1038/mt.2011.190>
- 832 Bazak, R., Hourri, M., el Achy, S., Kamel, S., Refaat, T., 2015. Cancer active targeting by  
833 nanoparticles: a comprehensive review of literature. *J Cancer Res Clin Oncol* 141, 769–  
834 784. <https://doi.org/10.1007/s00432-014-1767-3>
- 835 BOLTE, S., CORDELIÈRES, F.P., 2006. A guided tour into subcellular colocalization analysis in  
836 light microscopy. *J Microsc* 224, 213–232. <https://doi.org/10.1111/j.1365->  
837 [2818.2006.01706.x](https://doi.org/10.1111/j.1365-2818.2006.01706.x)
- 838 Browne, K.A., Blink, E., Sutton, V.R., Froelich, C.J., Jans, D.A., Trapani, J.A., 1999. Cytosolic  
839 Delivery of Granzyme B by Bacterial Toxins: Evidence that Endosomal Disruption, in  
840 Addition to Transmembrane Pore Formation, Is an Important Function of Perforin. *Mol*  
841 *Cell Biol* 19, 8604–8615. <https://doi.org/10.1128/MCB.19.12.8604>
- 842 Burks, S.R., Legenzov, E.A., Martin, E.W., Li, C., Lu, W., Kao, J.P.Y., 2015. Co-Encapsulating the  
843 Fusogenic Peptide INF7 and Molecular Imaging Probes in Liposomes Increases  
844 Intracellular Signal and Probe Retention. *PLoS One* 10, e0120982.  
845 <https://doi.org/10.1371/journal.pone.0120982>
- 846 Casanova, I., Unzueta, U., Arroyo-Solera, I., Céspedes, M.V., Villaverde, A., Mangués, R.,  
847 Vázquez, E., 2019. Protein-driven nanomedicines in oncotherapy. *Curr Opin Pharmacol*  
848 47, 1–7. <https://doi.org/10.1016/j.coph.2018.12.004>
- 849 Chanoca, A., Otegui, M.S., 2014. Immunogold Labeling and Electron Tomography of Plant  
850 Endosomes. pp. 63–80. [https://doi.org/10.1007/978-1-4939-1420-3\\_5](https://doi.org/10.1007/978-1-4939-1420-3_5)
- 851 Chao, T.-Y., Raines, R.T., 2013. Fluorogenic label to quantify the cytosolic delivery of  
852 macromolecules. *Mol Biosyst* 9, 339. <https://doi.org/10.1039/c3mb25552b>
- 853 Corchero, J.L., Vázquez, E., García-Fruitós, E., Ferrer-Miralles, N., Villaverde, A., 2014.  
854 Recombinant protein materials for bioengineering and nanomedicine. *Nanomedicine* 9,  
855 2817–2828. <https://doi.org/10.2217/nnm.14.153>
- 856 Deprey, K., Becker, L., Kritzer, J., Plückthun, A., 2019. Trapped! A Critical Evaluation of Methods  
857 for Measuring Total Cellular Uptake versus Cytosolic Localization. *Bioconjug Chem* 30,  
858 1006–1027. <https://doi.org/10.1021/acs.bioconjchem.9b00112>
- 859 Dhankher, A., Lv, W., Studstill, W.T., Champion, J.A., 2021. Coiled coil exposure and histidine  
860 tags drive function of an intracellular protein drug carrier. *Journal of Controlled Release*  
861 339, 248–258. <https://doi.org/10.1016/j.jconrel.2021.09.026>
- 862 Díaz, R., Pallarès, V., Cano-Garrido, O., Serna, N., Sánchez-García, L., Falgàs, A., Pesarrodonà,  
863 M., Unzueta, U., Sánchez-Chardi, A., Sánchez, J.M., Casanova, I., Vázquez, E., Mangués, R.,  
864 Villaverde, A., 2018. Selective CXCR4 Cancer Cell Targeting and Potent Antineoplastic

865 Effect by a Nanostructured Version of Recombinant Ricin. *Small* 14, 1800665.  
866 <https://doi.org/10.1002/sml.201800665>

867 Duncan, R., Gaspar, R., 2011. Nanomedicine(s) under the Microscope. *Mol Pharm* 8, 2101–  
868 2141. <https://doi.org/10.1021/mp200394t>

869 Dyer, P.D.R., Shepherd, T.R., Gollings, A.S., Shorter, S.A., Gorringe-Patrick, M.A.M., Tang, C.-K.,  
870 Cattoz, B.N., Baillie, L., Griffiths, P.C., Richardson, S.C.W., 2015. Disarmed anthrax toxin  
871 delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.  
872 *Journal of Controlled Release* 220, 316–328.  
873 <https://doi.org/10.1016/j.jconrel.2015.10.054>

874 Erazo-Oliveras, A., Najjar, K., Dayani, L., Wang, T.-Y., Johnson, G.A., Pellois, J.-P., 2014. Protein  
875 delivery into live cells by incubation with an endosomolytic agent. *Nat Methods* 11, 861–  
876 867. <https://doi.org/10.1038/nmeth.2998>

877 Erazo-Oliveras, A., Najjar, K., Truong, D., Wang, T.-Y., Brock, D.J., Prater, A.R., Pellois, J.-P.,  
878 2016. The Late Endosome and Its Lipid BMP Act as Gateways for Efficient Cytosolic Access  
879 of the Delivery Agent dTAT and Its Macromolecular Cargos. *Cell Chem Biol* 23, 598–607.  
880 <https://doi.org/10.1016/j.chembiol.2016.03.016>

881 Erickson, H.A., Jund, M.D., Pennell, C.A., 2006. Cytotoxicity of human RNase-based  
882 immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. *Protein*  
883 *Engineering, Design and Selection* 19, 37–45. <https://doi.org/10.1093/protein/gzi073>

884 Evans, B.C., Nelson, C.E., Yu, S.S., Beavers, K.R., Kim, A.J., Li, H., Nelson, H.M., Giorgio, T.D.,  
885 Duvall, C.L., 2013. Ex Vivo Red Blood Cell Hemolysis Assay for the Evaluation of pH-  
886 responsive Endosomolytic Agents for Cytosolic Delivery of Biomacromolecular Drugs.  
887 *Journal of Visualized Experiments*. <https://doi.org/10.3791/50166>

888 Falnes, P., Wiedlocha, A., Rapak, A., Olsnes, S., 1995. Farnesylation of CaaX-Tagged Diphtheria  
889 Toxin A-Fragment as a Measure of Transfer to the Cytosol. *Biochemistry* 34, 11152–  
890 11159. <https://doi.org/10.1021/bi00035a021>

891 Fernandez, D.I., le Brun, A.P., Whitwell, T.C., Sani, M.-A., James, M., Separovic, F., 2012. The  
892 antimicrobial peptide aurein 1.2 disrupts model membranes via the carpet mechanism.  
893 *Physical Chemistry Chemical Physics* 14, 15739. <https://doi.org/10.1039/c2cp43099a>

894 Ferrer-Miralles, N., Rodríguez-Carmona, E., Corchero, J.L., García-Fruitós, E., Vázquez, E.,  
895 Villaverde, A., 2015. Engineering protein self-assembling in protein-based nanomedicines  
896 for drug delivery and gene therapy. *Crit Rev Biotechnol* 35, 209–221.  
897 <https://doi.org/10.3109/07388551.2013.833163>

898 Fotoohi-Ardakani, G., Kheirollahi, M., Zarei Jaliani, H., Noorian, M., Ansariniyia, H., 2019.  
899 Targeting MCF-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion with AHNP  
900 Targeted Peptide. *Adv Biomed Res* 8, 33. [https://doi.org/10.4103/abr.abr\\_18\\_19](https://doi.org/10.4103/abr.abr_18_19)

901 Friebe, S., van der Goot, F., Bürgi, J., 2016. The Ins and Outs of Anthrax Toxin. *Toxins (Basel)* 8,  
902 69. <https://doi.org/10.3390/toxins8030069>

903 Fuchs, H., Bachran, C., Li, T., Heisler, I., Dürkop, H., Sutherland, M., 2007. A cleavable molecular  
904 adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by

905 targeted toxins in mice. *Journal of Controlled Release* 117, 342–350.  
906 <https://doi.org/10.1016/j.jconrel.2006.11.019>

907 Garcia-Castillo, M.D., Tran, T., Bobard, A., Renard, H.-F., Rathjen, S.J., Dransart, E., Stechmann,  
908 B., Lamaze, C., Lord, M., Cintrat, J.-C., Enninga, J., Tartour, E., Johannes, L., 2015.  
909 Retrograde transport is not required for cytosolic translocation of the B-subunit of Shiga  
910 toxin. *J Cell Sci* 128, 2373–2387. <https://doi.org/10.1242/jcs.169383>

911 Gilyazova, D.G., Rosenkranz, A.A., Gulak, P. v., Lunin, V.G., Sergienko, O. v., Khramtsov, Y. v.,  
912 Timofeyev, K.N., Grin, M.A., Mironov, A.F., Rubin, A.B., Georgiev, G.P., Sobolev, A.S.,  
913 2006. Targeting Cancer Cells by Novel Engineered Modular Transporters. *Cancer Res* 66,  
914 10534–10540. <https://doi.org/10.1158/0008-5472.CAN-06-2393>

915 Guzmán, F.A., Arneodo, J.D., Saavedra Pons, A.B., Truol, G.A., Luque, A. v., Conci, L.R., 2010.  
916 Immunodetection and subcellular localization of Mal de Río Cuarto virus P9-1 protein in  
917 infected plant and insect host cells. *Virus Genes* 41, 111–117.  
918 <https://doi.org/10.1007/s11262-010-0480-9>

919 Hajimolaali, M., Mohammadian, H., Torabi, A., Shirini, A., Khalife Shal, M., Barazandeh Nezhad,  
920 H., Iranpour, S., Baradaran Eftekhari, R., Dorkoosh, F., 2021. Application of chloroquine as  
921 an endosomal escape enhancing agent: new frontiers for an old drug. *Expert Opin Drug*  
922 *Deliv* 18, 877–889. <https://doi.org/10.1080/17425247.2021.1873272>

923 Hama, S., Akita, H., Ito, R., Mizuguchi, H., Hayakawa, T., Harashima, H., 2006. Quantitative  
924 Comparison of Intracellular Trafficking and Nuclear Transcription between Adenoviral  
925 and Lipoplex Systems. *Molecular Therapy* 13, 786–794.  
926 <https://doi.org/10.1016/j.ymthe.2005.10.007>

927 Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., Harashima, H., 2009. A pH-  
928 sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene  
929 silencing of siRNA-containing nanoparticles in vitro and in vivo. *Journal of Controlled*  
930 *Release* 139, 127–132. <https://doi.org/10.1016/j.jconrel.2009.06.008>

931 He, J., Xu, S., Mixson, A.J., 2020. The Multifaceted Histidine-Based Carriers for Nucleic Acid  
932 Delivery: Advances and Challenges. *Pharmaceutics* 12, 774.  
933 <https://doi.org/10.3390/pharmaceutics12080774>

934 Hetzel, C., Bachran, C., Fischer, R., Fuchs, H., Barth, S., Stöcker, M., 2008. Small Cleavable  
935 Adapters Enhance the Specific Cytotoxicity of a Humanized Immunotoxin Directed  
936 Against CD64-positive Cells. *Journal of Immunotherapy* 31, 370–376.  
937 <https://doi.org/10.1097/CJI.0b013e31816a2d23>

938 Hu, Y., Litwin, T., Nagaraja, A.R., Kwong, B., Katz, J., Watson, N., Irvine, D.J., 2007. Cytosolic  
939 Delivery of Membrane-Impermeable Molecules in Dendritic Cells Using pH-Responsive  
940 Core-Shell Nanoparticles. *Nano Lett* 7, 3056–3064. <https://doi.org/10.1021/nl071542i>

941 Huang, C.Y.-H., Butrapet, S., Moss, K.J., Childers, T., Erb, S.M., Calvert, A.E., Silengo, S.J.,  
942 Kinney, R.M., Blair, C.D., Roehrig, J.T., 2010. The dengue virus type 2 envelope protein  
943 fusion peptide is essential for membrane fusion. *Virology* 396, 305–315.  
944 <https://doi.org/10.1016/j.virol.2009.10.027>

945 Huotari, J., Helenius, A., 2011. Endosome maturation. *EMBO J* 30, 3481–3500.  
946 <https://doi.org/10.1038/emboj.2011.286>

- 947 Inoue, T., Moore, P., Tsai, B., 2011. How Viruses and Toxins Disassemble to Enter Host Cells.  
948 *Annu Rev Microbiol* 65, 287–305. [https://doi.org/10.1146/annurev-micro-090110-](https://doi.org/10.1146/annurev-micro-090110-102855)  
949 102855
- 950 Jiang, Y., Lu, Q., Wang, Yongheng, Xu, E., Ho, A., Singh, P., Wang, Yifei, Jiang, Z., Yang, F.,  
951 Tietjen, G.T., Cresswell, P., Saltzman, W.M., 2020. Quantitating Endosomal Escape of a  
952 Library of Polymers for mRNA Delivery. *Nano Lett* 20, 1117–1123.  
953 <https://doi.org/10.1021/acs.nanolett.9b04426>
- 954 Jiang, Z., Guan, J., Qian, J., Zhan, C., 2019. Peptide ligand-mediated targeted drug delivery of  
955 nanomedicines. *Biomater Sci* 7, 461–471. <https://doi.org/10.1039/C8BM01340C>
- 956 Kakimoto, S., Hamada, T., Komatsu, Y., Takagi, M., Tanabe, T., Azuma, H., Shinkai, S., Nagasaki,  
957 T., 2009. The conjugation of diphtheria toxin T domain to poly(ethylenimine) based  
958 vectors for enhanced endosomal escape during gene transfection. *Biomaterials* 30, 402–  
959 408. <https://doi.org/10.1016/j.biomaterials.2008.09.042>
- 960 Kandil, R., Xie, Y., Heermann, R., Isert, L., Jung, K., Mehta, A., Merkel, O.M., 2019. Coming in  
961 and Finding Out: Blending Receptor-Targeted Delivery and Efficient Endosomal Escape in  
962 a Novel Bio-Responsive siRNA Delivery System for Gene Knockdown in Pulmonary T Cells.  
963 *Adv Ther (Weinh)* 1900047. <https://doi.org/10.1002/adtp.201900047>
- 964 Kato, T., Yamashita, H., Misawa, T., Nishida, K., Kurihara, M., Tanaka, M., Demizu, Y., Oba, M.,  
965 2016. Plasmid DNA delivery by arginine-rich cell-penetrating peptides containing  
966 unnatural amino acids. *Bioorg Med Chem* 24, 2681–2687.  
967 <https://doi.org/10.1016/j.bmc.2016.04.031>
- 968 Kheirandish, M.H., Jaliani, H.Z., Rahmani, B., Nikukar, H., 2019. Specific targeting of a pore-  
969 forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.  
970 *Toxicon* 164, 82–86. <https://doi.org/10.1016/j.toxicon.2019.04.005>
- 971 Kiesgen, S., Liebers, N., Cremer, M., Arnold, U., Weber, T., Keller, A., Herold-Mende, C.,  
972 Dyckhoff, G., Jager, D., Kontermann, R.E., Arndt, M.A.E., Krauss, J., 2014. A fusogenic  
973 dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease  
974 fusion protein targeting the EGF receptor. *Protein Engineering Design and Selection* 27,  
975 331–338. <https://doi.org/10.1093/protein/gzu040>
- 976 Kim, A., Miura, Y., Ishii, T., Mutaf, O.F., Nishiyama, N., Cabral, H., Kataoka, K., 2016.  
977 Intracellular Delivery of Charge-Converted Monoclonal Antibodies by Combinatorial  
978 Design of Block/Homo Polyion Complex Micelles. *Biomacromolecules* 17, 446–453.  
979 <https://doi.org/10.1021/acs.biomac.5b01335>
- 980 Kim, J., Choi, D.-K., Park, S., Shin, S.-M., Bae, J., Kim, D.-M., Yoo, T.H., Kim, Y.-S., 2015.  
981 Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells  
982 by an enhanced split GFP complementation assay. *Biochem Biophys Res Commun* 467,  
983 771–777. <https://doi.org/10.1016/j.bbrc.2015.10.066>
- 984 Kim, J., Park, J.-Y., Shin, S.-M., Park, S.-W., Jun, S.-Y., Hong, J.-S., Choi, D.-K., Kim, Y.-S., 2018.  
985 Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal  
986 escape efficacy. *Biochem Biophys Res Commun* 503, 2510–2516.  
987 <https://doi.org/10.1016/j.bbrc.2018.07.008>

- 988 Kim, J.-S., Choi, D.-K., Shin, J.-Y., Shin, S.-M., Park, S.-W., Cho, H.-S., Kim, Y.-S., 2016. Endosomal  
989 acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate  
990 endosomal escape. *Journal of Controlled Release* 235, 165–175.  
991 <https://doi.org/10.1016/j.jconrel.2016.05.066>
- 992 Kobayashi, T., Startchev, K., Whitney, A.J., Gruenberg, J., 2001. Localization of  
993 Lysobisphosphatidic Acid-Rich Membrane Domains in Late Endosomes. *Biol Chem* 382.  
994 <https://doi.org/10.1515/BC.2001.059>
- 995 Ladokhin, A.S., Kyrychenko, A., Rodnin, M. v., Vasquez-Montes, V., 2021. Conformational  
996 switching, refolding and membrane insertion of the diphtheria toxin translocation  
997 domain. pp. 341–370. <https://doi.org/10.1016/bs.mie.2020.12.016>
- 998 LeCher, J.C., Nowak, S.J., McMurry, J.L., 2017. Breaking in and busting out: cell-penetrating  
999 peptides and the endosomal escape problem. *Biomol Concepts* 8, 131–141.  
1000 <https://doi.org/10.1515/bmc-2017-0023>
- 1001 Lee, Y.H., Tan, H.T., Chung, M.C.M., 2010. Subcellular fractionation methods and strategies for  
1002 proteomics. *Proteomics* 10, 3935–3956. <https://doi.org/10.1002/pmic.201000289>
- 1003 Lee, Y.-J., Datta, S., Pellois, J.-P., 2008. Real-Time Fluorescence Detection of Protein  
1004 Transduction into Live Cells. *J Am Chem Soc* 130, 2398–2399.  
1005 <https://doi.org/10.1021/ja7102026>
- 1006 Lee, Y.-J., Johnson, G., Peltier, G.C., Pellois, J.-P., 2011. A HA2-Fusion tag limits the endosomal  
1007 release of its protein cargo despite causing endosomal lysis. *Biochimica et Biophysica*  
1008 *Acta (BBA) - General Subjects* 1810, 752–758.  
1009 <https://doi.org/10.1016/j.bbagen.2011.05.013>
- 1010 Lee, Y.-W., Luther, D.C., Kretzmann, J.A., Burden, A., Jeon, T., Zhai, S., Rotello, V.M., 2019.  
1011 Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers. *Theranostics* 9, 3280–  
1012 3292. <https://doi.org/10.7150/thno.34412>
- 1013 Li, C., Cao, X.-W., Zhao, J., Wang, F.-J., 2020. Effective Therapeutic Drug Delivery by GALA3, an  
1014 Endosomal Escape Peptide with Reduced Hydrophobicity. *J Membr Biol* 253, 139–152.  
1015 <https://doi.org/10.1007/s00232-020-00109-2>
- 1016 Li, M., Tao, Y., Shu, Y., LaRochelle, J.R., Steinauer, A., Thompson, D., Schepartz, A., Chen, Z.-Y.,  
1017 Liu, D.R., 2015. Discovery and Characterization of a Peptide That Enhances Endosomal  
1018 Escape of Delivered Proteins in Vitro and in Vivo. *J Am Chem Soc* 137, 14084–14093.  
1019 <https://doi.org/10.1021/jacs.5b05694>
- 1020 Liao, X., Rabideau, A.E., Pentelute, B.L., 2014. Delivery of Antibody Mimics into Mammalian  
1021 Cells via Anthrax Toxin Protective Antigen. *ChemBioChem* 15, 2458–2466.  
1022 <https://doi.org/10.1002/cbic.201402290>
- 1023 Lieser, R.M., Li, Q., Chen, W., Sullivan, M.O., 2022. Incorporation of Endosomolytic Peptides  
1024 with Varying Disruption Mechanisms into EGFR-Targeted Protein Conjugates: The Effect  
1025 on Intracellular Protein Delivery and EGFR Specificity in Breast Cancer Cells. *Mol Pharm*  
1026 19, 661–673. <https://doi.org/10.1021/acs.molpharmaceut.1c00788>

- 1027 Lin, N., Zheng, W., Li, L., Liu, H., Wang, T., Wang, P., Ma, X., 2014. A novel system enhancing  
1028 the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung  
1029 cancer A549 cells. *Target Oncol* 9, 163–170. <https://doi.org/10.1007/s11523-013-0282-9>
- 1030 Liu, S., Wang, B., Sheng, Y., Dong, S., Liu, G., 2022. Rational Design of Self-Assembled  
1031 Mitochondria-Targeting Lytic Peptide Conjugates with Enhanced Tumor Selectivity.  
1032 *Chemistry – A European Journal* 28. <https://doi.org/10.1002/chem.202103517>
- 1033 Liu, X., Zhang, P., Rödl, W., Maier, K., Lächelt, U., Wagner, E., 2017. Toward Artificial  
1034 Immunotoxins: Traceless Reversible Conjugation of RNase A with Receptor Targeting and  
1035 Endosomal Escape Domains. *Mol Pharm* 14, 1439–1449.  
1036 <https://doi.org/10.1021/acs.molpharmaceut.6b00701>
- 1037 Loison, F., Nizard, P., Sourisseau, T., le Goff, P., Debure, L., le Drean, Y., Michel, D., 2005. A  
1038 ubiquitin-based assay for the cytosolic uptake of protein transduction domains.  
1039 *Molecular Therapy* 11, 205–214. <https://doi.org/10.1016/j.ymthe.2004.10.010>
- 1040 Lönn, P., Dowdy, S.F., 2015. Cationic PTD/PPP-mediated macromolecular delivery: charging  
1041 into the cell. *Expert Opin Drug Deliv* 12, 1627–1636.  
1042 <https://doi.org/10.1517/17425247.2015.1046431>
- 1043 Lönn, P., Kacsinta, A.D., Cui, X.-S., Hamil, A.S., Kaulich, M., Gogoi, K., Dowdy, S.F., 2016.  
1044 Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic  
1045 Therapeutics. *Sci Rep* 6, 32301. <https://doi.org/10.1038/srep32301>
- 1046 López-Laguna, H., Cubarsi, R., Unzueta, U., Mangués, R., Vázquez, E., Villaverde, A., 2020.  
1047 Endosomal escape of protein nanoparticles engineered through humanized histidine-rich  
1048 peptides. *Sci China Mater* 63, 644–653. <https://doi.org/10.1007/s40843-019-1231-y>
- 1049 López-Laguna, H., Voltà-Durán, E., Parladé, E., Villaverde, A., Vázquez, E., Unzueta, U., 2022.  
1050 Insights on the emerging biotechnology of histidine-rich peptides. *Biotechnol Adv* 54,  
1051 107817. <https://doi.org/10.1016/j.biotechadv.2021.107817>
- 1052 Lundberg, P., El-Andaloussi, S., Sützlü, T., Johansson, H., Langel, Ü., 2007. Delivery of short  
1053 interfering RNA using endosomolytic cell-penetrating peptides. *The FASEB Journal* 21,  
1054 2664–2671. <https://doi.org/10.1096/fj.06-6502com>
- 1055 Madani, F., Abdo, R., Lindberg, S., Hirose, H., Futaki, S., Langel, Ü., Gräslund, A., 2013.  
1056 Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH  
1057 gradient. *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1828, 1198–1204.  
1058 <https://doi.org/10.1016/j.bbamem.2012.12.008>
- 1059 Madani, F., Perálvarez-Marín, A., Gräslund, A., 2011. Liposome Model Systems to Study the  
1060 Endosomal Escape of Cell-Penetrating Peptides: Transport across Phospholipid  
1061 Membranes Induced by a Proton Gradient. *J Drug Deliv* 2011, 1–7.  
1062 <https://doi.org/10.1155/2011/897592>
- 1063 Maier, K., Martin, I., Wagner, E., 2012. Sequence Defined Disulfide-Linked Shuttle for Strongly  
1064 Enhanced Intracellular Protein Delivery. *Mol Pharm* 9, 3560–3568.  
1065 <https://doi.org/10.1021/mp300404d>
- 1066 Mantis, N. (Ed.), 2012. *Ricin and Shiga Toxins*. Springer Berlin Heidelberg, Berlin, Heidelberg.  
1067 <https://doi.org/10.1007/978-3-642-27470-1>



- 1068 Martens, T.F., Remaut, K., Demeester, J., de Smedt, S.C., Braeckmans, K., 2014. Intracellular  
1069 delivery of nanomaterials: How to catch endosomal escape in the act. *Nano Today* 9,  
1070 344–364. <https://doi.org/10.1016/j.nantod.2014.04.011>
- 1071 Matsuzaki, K., 2019. Membrane Permeabilization Mechanisms. pp. 9–16.  
1072 [https://doi.org/10.1007/978-981-13-3588-4\\_2](https://doi.org/10.1007/978-981-13-3588-4_2)
- 1073 Mayer, S.F., Ducrey, J., Dupasquier, J., Haeni, L., Rothen-Rutishauser, B., Yang, J., Fennouri, A.,  
1074 Mayer, M., 2019. Targeting specific membranes with an azide derivative of the pore-  
1075 forming peptide ceratotoxin A. *Biochimica et Biophysica Acta (BBA) - Biomembranes*  
1076 1861, 183023. <https://doi.org/10.1016/j.bbamem.2019.07.011>
- 1077 Mejia, F., Khan, S., Omstead, D.T., Minetos, C., Bilgicer, B., 2022. Identification and  
1078 optimization of tunable endosomal escape parameters for enhanced efficacy in peptide-  
1079 targeted prodrug-loaded nanoparticles. *Nanoscale* 14, 1226–1240.  
1080 <https://doi.org/10.1039/D1NR05357D>
- 1081 Mellert, K., Lamla, M., Scheffzek, K., Wittig, R., Kaufmann, D., 2012. Enhancing Endosomal  
1082 Escape of Transduced Proteins by Photochemical Internalisation. *PLoS One* 7, e52473.  
1083 <https://doi.org/10.1371/journal.pone.0052473>
- 1084 Michalska, M., Wolf, P., 2015. Pseudomonas Exotoxin A: optimized by evolution for effective  
1085 killing. *Front Microbiol* 6. <https://doi.org/10.3389/fmicb.2015.00963>
- 1086 Mohammed, A.F., Abdul-Wahid, A., Huang, E.H.-B., Bolewska-Pedyczak, E., Cydzik, M., Broad,  
1087 A.E., Gariépy, J., 2012. The Pseudomonas aeruginosa exotoxin A translocation domain  
1088 facilitates the routing of CPP–protein cargos to the cytosol of eukaryotic cells. *Journal of*  
1089 *Controlled Release* 164, 58–64. <https://doi.org/10.1016/j.jconrel.2012.10.006>
- 1090 Morito, D., Nagata, K., 2015. Pathogenic Hijacking of ER-Associated Degradation: Is ERAD  
1091 Flexible? *Mol Cell* 59, 335–344. <https://doi.org/10.1016/j.molcel.2015.06.010>
- 1092 Nakase, I., Kogure, K., Harashima, H., Futaki, S., 2011. Application of a Fusiogenic Peptide GALA  
1093 for Intracellular Delivery. pp. 525–533. [https://doi.org/10.1007/978-1-60761-919-2\\_37](https://doi.org/10.1007/978-1-60761-919-2_37)
- 1094 Niikura, K., Horisawa, K., Doi, N., 2016. Endosomal escape efficiency of fusogenic B18 and B55  
1095 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation. *J*  
1096 *Biochem* 159, 123–132. <https://doi.org/10.1093/jb/mvv083>
- 1097 Niikura, K., Horisawa, K., Doi, N., 2015. A fusogenic peptide from a sea urchin fertilization  
1098 protein promotes intracellular delivery of biomacromolecules by facilitating endosomal  
1099 escape. *J Control Release* 212, 85–93. <https://doi.org/10.1016/j.jconrel.2015.06.020>
- 1100 Nowakowska-Gołacka, J., Sominka, H., Sowa-Rogozńska, N., Słomińska-Wojewódzka, M., 2019.  
1101 Toxins Utilize the Endoplasmic Reticulum-Associated Protein Degradation Pathway in  
1102 Their Intoxication Process. *Int J Mol Sci* 20, 1307. <https://doi.org/10.3390/ijms20061307>
- 1103 Oess, S., Hildt, E., 2000. Novel cell permeable motif derived from the PreS2-domain of  
1104 hepatitis-B virus surface antigens. *Gene Ther* 7, 750–758.  
1105 <https://doi.org/10.1038/sj.gt.3301154>
- 1106 Oude Blenke, E., Sleszynska, M., Evers, M.J.W., Storm, G., Martin, N.I., Mastrobattista, E., 2017.  
1107 Strategies for the Activation and Release of the Membranolytic Peptide Melittin from

1108 Liposomes Using Endosomal pH as a Trigger. *Bioconjug Chem* 28, 574–582.  
1109 <https://doi.org/10.1021/acs.bioconjchem.6b00677>

1110 Pal, D., 2021. Spike protein fusion loop controls SARS-CoV-2 fusogenicity and infectivity. *J*  
1111 *Struct Biol* 213, 107713. <https://doi.org/10.1016/j.jsb.2021.107713>

1112 Paray, B.A., Ahmad, A., Khan, J.M., Taufiq, F., Pathan, A., Malik, A., Ahmed, M.Z., 2021. The  
1113 role of the multifunctional antimicrobial peptide melittin in gene delivery. *Drug Discov*  
1114 *Today* 26, 1053–1059. <https://doi.org/10.1016/j.drudis.2021.01.004>

1115 Pei, D., 2022. How Do Biomolecules Cross the Cell Membrane? *Acc Chem Res* 55, 309–318.  
1116 <https://doi.org/10.1021/acs.accounts.1c00560>

1117 Pei, D., Buyanova, M., 2019. Overcoming Endosomal Entrapment in Drug Delivery. *Bioconjug*  
1118 *Chem* 30, 273–283. <https://doi.org/10.1021/acs.bioconjchem.8b00778>

1119 Peters, P.J., Borst, J., Oorschot, V., Fukuda, M., Krähenbühl, O., Tschopp, J., Slot, J.W., Geuze,  
1120 H.J., 1991. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both  
1121 perforin and granzymes. *Journal of Experimental Medicine* 173, 1099–1109.  
1122 <https://doi.org/10.1084/jem.173.5.1099>

1123 Peters, P.J., Bos, E., Griekspoor, A., 2006. Cryo-Immunogold Electron Microscopy. *Curr Protoc*  
1124 *Cell Biol* 30. <https://doi.org/10.1002/0471143030.cb0407s30>

1125 Pirie, C.M., Hackel, B.J., Rosenblum, M.G., Wittrup, K.D., 2011. Convergent Potency of  
1126 Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting  
1127 Moieties. *Journal of Biological Chemistry* 286, 4165–4172.  
1128 <https://doi.org/10.1074/jbc.M110.186973>

1129 Plaza-GA, I., Manzaneda-González, V., Kisovec, M., Almendro-Vedia, V., Muñoz-Úbeda, M.,  
1130 Anderluh, G., Guerrero-Martínez, A., Natale, P., López Montero, I., 2019. pH-triggered  
1131 endosomal escape of pore-forming Listeriolysin O toxin-coated gold nanoparticles. *J*  
1132 *Nanobiotechnology* 17, 108. <https://doi.org/10.1186/s12951-019-0543-6>

1133 Prchla, E., Plank, C., Wagner, E., Blaas, D., Fuchs, R., 1995. Virus-mediated release of  
1134 endosomal content in vitro: different behavior of adenovirus and rhinovirus serotype 2.  
1135 *Journal of Cell Biology* 131, 111–123. <https://doi.org/10.1083/jcb.131.1.111>

1136 Priyadarshini, D., Ivica, J., Separovic, F., de Planque, M.R.R., 2022. Characterisation of cell  
1137 membrane interaction mechanisms of antimicrobial peptides by electrical bilayer  
1138 recording. *Biophys Chem* 281, 106721. <https://doi.org/10.1016/j.bpc.2021.106721>

1139 Quarta, A., Rodio, M., Cassani, M., Gigli, G., Pellegrino, T., del Mercato, L.L., 2017. Multilayered  
1140 Magnetic Nanobeads for the Delivery of Peptides Molecules Triggered by Intracellular  
1141 Proteases. *ACS Appl Mater Interfaces* 9, 35095–35104.  
1142 <https://doi.org/10.1021/acsami.7b05709>

1143 Raj, S., Khurana, S., Choudhari, R., Kesari, K.K., Kamal, M.A., Garg, N., Ruokolainen, J., Das, B.C.,  
1144 Kumar, D., 2021. Specific targeting cancer cells with nanoparticles and drug delivery in  
1145 cancer therapy. *Semin Cancer Biol* 69, 166–177.  
1146 <https://doi.org/10.1016/j.semcancer.2019.11.002>

- 1147 Richardson, S.C.W., Patrick, N.G., Lavignac, N., Ferruti, P., Duncan, R., 2010. Intracellular fate  
1148 of bioresponsive poly(amidoamine)s in vitro and in vivo. *Journal of Controlled Release*  
1149 142, 78–88. <https://doi.org/10.1016/j.jconrel.2009.09.025>
- 1150 Rouet, R., Christ, D., 2019. Efficient Intracellular Delivery of CRISPR-Cas Ribonucleoproteins  
1151 through Receptor Mediated Endocytosis. *ACS Chem Biol* 14, 554–561.  
1152 <https://doi.org/10.1021/acscchembio.9b00116>
- 1153 Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S.,  
1154 Harashima, H., 2011. Endosomal escape and the knockdown efficiency of liposomal-  
1155 siRNA by the fusogenic peptide shGALA. *Biomaterials* 32, 5733–5742.  
1156 <https://doi.org/10.1016/j.biomaterials.2011.04.047>
- 1157 Sala, R., Sánchez-García, L., Serna, N., Céspedes, M.V., Casanova, I., Roldán, M., Sánchez-  
1158 Chardi, A., Unzueta, U., Vázquez, E., Mangués, R., Villaverde, A., 2019. Collaborative  
1159 membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle  
1160 delivery in CXCR4+ colorectal cancer. *Acta Biomater* 99, 426–432.  
1161 <https://doi.org/10.1016/j.actbio.2019.09.002>
- 1162 Salomone, F., Cardarelli, F., di Luca, M., Boccardi, C., Nifosì, R., Bardi, G., di Bari, L., Serresi, M.,  
1163 Beltram, F., 2012. A novel chimeric cell-penetrating peptide with membrane-disruptive  
1164 properties for efficient endosomal escape. *Journal of Controlled Release* 163, 293–303.  
1165 <https://doi.org/10.1016/j.jconrel.2012.09.019>
- 1166 Sánchez-García, L., Serna, N., Álamo, P., Sala, R., Céspedes, M.V., Roldan, M., Sánchez-Chardi,  
1167 A., Unzueta, U., Casanova, I., Mangués, R., Vázquez, E., Villaverde, A., 2018. Self-  
1168 assembling toxin-based nanoparticles as self-delivered antitumoral drugs. *Journal of*  
1169 *Controlled Release* 274, 81–92. <https://doi.org/10.1016/j.jconrel.2018.01.031>
- 1170 Sánchez-García, L., Serna, N., Mattanovich, M., Cazzanelli, P., Sánchez-Chardi, A., Conchillo-  
1171 Solé, O., Cortés, F., Daura, X., Unzueta, U., Mangués, R., Villaverde, A., Vázquez, E., 2017.  
1172 The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles.  
1173 *Chemical Communications* 53, 4565–4568. <https://doi.org/10.1039/C6CC09900A>
- 1174 Schmit, N.E., Neopane, K., Hantschel, O., 2019. Targeted Protein Degradation through Cytosolic  
1175 Delivery of Monobody Binders Using Bacterial Toxins. *ACS Chem Biol* 14, 916–924.  
1176 <https://doi.org/10.1021/acscchembio.9b00113>
- 1177 Schuster, M., Schnell, L., Feigl, P., Birkhofer, C., Mohr, K., Roeder, M., Carle, S., Langer, S.,  
1178 Tippel, F., Buchner, J., Fischer, G., Hausch, F., Frick, M., Schwan, C., Aktories, K., Schiene-  
1179 Fischer, C., Barth, H., 2017. The Hsp90 machinery facilitates the transport of diphtheria  
1180 toxin into human cells. *Sci Rep* 7, 613. <https://doi.org/10.1038/s41598-017-00780-x>
- 1181 Selby, L.I., Cortez-Jugo, C.M., Such, G.K., Johnston, A.P.R., 2017. Nanoescapology: progress  
1182 toward understanding the endosomal escape of polymeric nanoparticles. *WIREs*  
1183 *Nanomedicine and Nanobiotechnology* 9. <https://doi.org/10.1002/wnan.1452>
- 1184 Serna, N., Sánchez, J.M., Unzueta, U., Sánchez-García, L., Sánchez-Chardi, A., Mangués, R.,  
1185 Vázquez, E., Villaverde, A., 2019. Recruiting potent membrane penetrability in tumor cell-  
1186 targeted protein-only nanoparticles. *Nanotechnology* 30, 115101.  
1187 <https://doi.org/10.1088/1361-6528/aaf959>

- 1188 Serna, N., Sánchez-García, L., Unzueta, U., Díaz, R., Vázquez, E., Mangues, R., Villaverde, A.,  
1189 2018. Protein-Based Therapeutic Killing for Cancer Therapies. *Trends Biotechnol* 36, 318–  
1190 335. <https://doi.org/10.1016/j.tibtech.2017.11.007>
- 1191 Smith, S.A., Selby, L.I., Johnston, A.P.R., Such, G.K., 2019. The Endosomal Escape of  
1192 Nanoparticles: Toward More Efficient Cellular Delivery. *Bioconjug Chem* 30, 263–272.  
1193 <https://doi.org/10.1021/acs.bioconjugchem.8b00732>
- 1194 Somiya, M., Kuroda, S., 2020. DDS Nanocarriers Mimicking Early Infection Machinery of  
1195 Viruses. *YAKUGAKU ZASSHI* 140, 147–152. <https://doi.org/10.1248/yakushi.19-00187-2>
- 1196 Sowa-Rogozińska, N., Sominka, H., Nowakowska-Gołacka, J., Sandvig, K., Słomińska-  
1197 Wojewódzka, M., 2019. Intracellular Transport and Cytotoxicity of the Protein Toxin Ricin.  
1198 *Toxins (Basel)* 11, 350. <https://doi.org/10.3390/toxins11060350>
- 1199 Sudo, K., Niikura, K., Iwaki, K., Kohyama, S., Fujiwara, K., Doi, N., 2017. Human-derived  
1200 fusogenic peptides for the intracellular delivery of proteins. *J Control Release* 255, 1–11.  
1201 <https://doi.org/10.1016/j.jconrel.2017.03.398>
- 1202 Sundan, A., Olsnes, S., Sandvig, K., Pihl, A., 1982. Preparation and properties of chimeric toxins  
1203 prepared from the constituent polypeptides of diphtheria toxin and ricin. Evidence for  
1204 entry of ricin A-chain via the diphtheria toxin pathway. *J Biol Chem* 257, 9733–9.
- 1205 Sung, M.S., Mun, J.-Y., Kwon, O., Kwon, K.-S., Oh, D.-B., 2013. Efficient myogenic differentiation  
1206 of human adipose-derived stem cells by the transduction of engineered MyoD protein.  
1207 *Biochem Biophys Res Commun* 437, 156–161.  
1208 <https://doi.org/10.1016/j.bbrc.2013.06.058>
- 1209 Tsai, B., Rodighiero, C., Lencer, W.I., Rapoport, T.A., 2001. Protein Disulfide Isomerase Acts as a  
1210 Redox-Dependent Chaperone to Unfold Cholera Toxin. *Cell* 104, 937–948.  
1211 [https://doi.org/10.1016/S0092-8674\(01\)00289-6](https://doi.org/10.1016/S0092-8674(01)00289-6)
- 1212 van Rossenberg, S.M.W., Sliedregt-Bol, K.M., Meeuwenoord, N.J., van Berkel, T.J.C., van Boom,  
1213 J.H., van der Marel, G.A., Biessen, E.A.L., 2002. Targeted Lysosome Disruptive Elements  
1214 for Improvement of Parenchymal Liver Cell-specific Gene Delivery. *Journal of Biological*  
1215 *Chemistry* 277, 45803–45810. <https://doi.org/10.1074/jbc.M203510200>
- 1216 Váňová, J., Čihařová, B., Hejtmánková, A., Epperla, C.P., Škvára, P., Forstová, J., Hubálek  
1217 Kalbáčová, M., Španielová, H., 2022. VirPorters: Insights into the action of cationic and  
1218 histidine-rich cell-penetrating peptides. *Int J Pharm* 611, 121308.  
1219 <https://doi.org/10.1016/j.ijpharm.2021.121308>
- 1220 Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., 2011. Endosomal escape pathways for  
1221 delivery of biologicals. *Journal of Controlled Release* 151, 220–228.  
1222 <https://doi.org/10.1016/j.jconrel.2010.11.004>
- 1223 Vasdekis, A.E., Scott, E.A., O’Neil, C.P., Psaltis, D., Hubbell, Jeffrey.A., 2012. Precision  
1224 Intracellular Delivery Based on Optofluidic Polymersome Rupture. *ACS Nano* 6, 7850–  
1225 7857. <https://doi.org/10.1021/nn302122h>
- 1226 Vazquez, E., Ferrer-Mirallas, N., Mangues, R., Corchero, J., Schwartz Jr., S., Villaverde, A., 2009.  
1227 Modular Protein Engineering in Emerging Cancer Therapies. *Curr Pharm Des* 15, 893–916.  
1228 <https://doi.org/10.2174/138161209787582084>

1229 Vercauteren, D., Deschout, H., Remaut, K., Engbersen, J.F.J., Jones, A.T., Demeester, J., de  
1230 Smedt, S.C., Braeckmans, K., 2011. Dynamic Colocalization Microscopy To Characterize  
1231 Intracellular Trafficking of Nanomedicines. *ACS Nano* 5, 7874–7884.  
1232 <https://doi.org/10.1021/nn2020858>

1233 Verdurmen, W.P.R., Mazlami, M., Plückthun, A., 2017. A Biotin Ligase-Based Assay for the  
1234 Quantification of the Cytosolic Delivery of Therapeutic Proteins. pp. 223–236.  
1235 [https://doi.org/10.1007/978-1-4939-6857-2\\_14](https://doi.org/10.1007/978-1-4939-6857-2_14)

1236 Voltà-Durán, E., Sánchez, J.M., Parladé, E., Serna, N., Vazquez, E., Unzueta, U., Villaverde, A.,  
1237 2022. The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer  
1238 Cell-Targeted Protein Nanoparticles. *Pharmaceutics* 14, 2644.  
1239 <https://doi.org/10.3390/pharmaceutics14122644>

1240 Wadia, J.S., Stan, R. v, Dowdy, S.F., 2004. Transducible TAT-HA fusogenic peptide enhances  
1241 escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med* 10, 310–315.  
1242 <https://doi.org/10.1038/nm996>

1243 Wensley, H.J., Johnston, D.A., Smith, W.S., Holmes, S.E., Flavell, S.U., Flavell, D.J., 2020. A Flow  
1244 Cytometric Method to Quantify the Endosomal Escape of a Protein Toxin to the Cytosol  
1245 of Target Cells. *Pharm Res* 37, 16. <https://doi.org/10.1007/s11095-019-2725-1>

1246 Wong, A.S.M., Mann, S.K., Czuba, E., Sahut, A., Liu, H., Suekama, T.C., Bickerton, T., Johnston,  
1247 A.P.R., Such, G.K., 2015. Self-assembling dual component nanoparticles with endosomal  
1248 escape capability. *Soft Matter* 11, 2993–3002. <https://doi.org/10.1039/C5SM00082C>

1249 Worch, R., 2014. Structural biology of the influenza virus fusion peptide. *Acta Biochim Pol* 61,  
1250 421–6.

1251 Yamashita, H., Demizu, Y., Shoda, T., Sato, Y., Oba, M., Tanaka, M., Kurihara, M., 2014.  
1252 Amphipathic short helix-stabilized peptides with cell-membrane penetrating ability.  
1253 *Bioorg Med Chem* 22, 2403–2408. <https://doi.org/10.1016/j.bmc.2014.03.005>

1254 Yang, S.-T., Zaitseva, E., Chernomordik, L. v., Melikov, K., 2010. Cell-Penetrating Peptide  
1255 Induces Leaky Fusion of Liposomes Containing Late Endosome-Specific Anionic Lipid.  
1256 *Biophys J* 99, 2525–2533. <https://doi.org/10.1016/j.bpj.2010.08.029>

1257 Yu, X., Xue, L., Zhao, J., Zhao, S., Wu, D., Liu, H.Y., 2021. Non-Cationic RGD-Containing Protein  
1258 Nanocarrier for Tumor-Targeted siRNA Delivery. *Pharmaceutics* 13, 2182.  
1259 <https://doi.org/10.3390/pharmaceutics13122182>

1260 Yuba, E., Kojima, C., Harada, A., Tana, Watarai, S., Kono, K., 2010. pH-Sensitive fusogenic  
1261 polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular  
1262 immunity. *Biomaterials* 31, 943–951. <https://doi.org/10.1016/j.biomaterials.2009.10.006>

1263 Zaitseva, E., Yang, S.-T., Melikov, K., Pourmal, S., Chernomordik, L. v., 2010. Dengue Virus  
1264 Ensures Its Fusion in Late Endosomes Using Compartment-Specific Lipids. *PLoS Pathog* 6,  
1265 e1001131. <https://doi.org/10.1371/journal.ppat.1001131>

1266

1267

1268

1269

1270

1271

1272